A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
Phase: PHASE3
Conditions: Pneumococcal Infections
Sponsor: Merck Sharp & Dohme LLC

Official Protocol Title: 
NCT number: 
NCT03620162  
Document Date: 
25-Jul-2018
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate
 the Interchangeability of V114 and Prevnar 13™ with Respect to 
Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-
DIRECTION)

PRODUCT: V114 
1
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Title Page
THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE 
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME 
CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. (MSD).
Protocol Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the 
Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and 
Immunogenicity in Healthy Infants (PNEU-DIRECTION)
Protocol Number: 027-00
Compound Number: V114
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey, 08889-0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
EudraCT
14115
2018-001151-12
Approval Date: 25-Jul-2018
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
2
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Sponsor Signatory
Typed Name:
Title:
Date
Protocol-specific Sponsor contact information can be found in the Investigator Study File 
Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol and 
to abide by all provisions of this protocol.
Typed Name:
Title:
Date
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
3
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Table of Contents
1
PROTOCOL SUMMARY ............................................................................................10
1.1
Synopsis.................................................................................................................10
1.2
Schema ..................................................................................................................15
1.3
Schedule of Activities (SoA) ................................................................................16
2
INTRODUCTION..........................................................................................................26
2.1
Study Rationale....................................................................................................26
2.2
Background ..........................................................................................................26
2.2.1
V114 and Pneumococcal Disease ................................................................26
2.2.2
Preclinical and Clinical Studies ...................................................................27
2.2.3
Information on Other Study-related Therapy ..............................................28
2.3
Benefit/Risk Assessment......................................................................................28
3
HYPOTHESIS, OBJECTIVES, AND ENDPOINTS .................................................28
4
STUDY DESIGN............................................................................................................31
4.1
Overall Design ......................................................................................................31
4.2
Scientific Rationale for Study Design.................................................................32
4.2.1
Rationale for Endpoints ...............................................................................33
4.2.1.1
Immunogenicity Endpoints................................................................33
4.2.1.2
Safety Endpoints ................................................................................34
4.2.1.3
Future Biomedical Research..............................................................34
4.2.2
Rationale for the Use of Comparator...........................................................34
4.3
Justification for Dose ...........................................................................................35
4.4
Beginning and End of Study Definition .............................................................35
4.4.1
Clinical Criteria for Early Study Termination .............................................35
5
STUDY POPULATION ................................................................................................35
5.1
Inclusion Criteria.................................................................................................36
5.2
Exclusion Criteria ................................................................................................36
5.3
Lifestyle Considerations ......................................................................................38
5.4
Screen Failures.....................................................................................................38
5.5
Participant Replacement Strategy......................................................................38
6
STUDY INTERVENTION............................................................................................38
6.1
Study Intervention(s) Administered...................................................................40
6.2
Preparation/Handling/Storage/Accountability .................................................41
6.2.1
Dose Preparation..........................................................................................41
6.2.2
Handling, Storage, and Accountability........................................................41
6.3
Measures to Minimize Bias: Randomization and Blinding..............................42
6.3.1
Intervention Assignment..............................................................................42
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
4
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
6.3.2
Stratification.................................................................................................42
6.3.3
Blinding........................................................................................................42
6.4
Study Intervention Compliance..........................................................................43
6.5
Concomitant Therapy..........................................................................................43
6.5.1
Rescue Medications and Supportive Care ...................................................45
6.6
Dose Modification (Escalation/Titration/Other)...............................................45
6.7
Intervention After the End of the Study............................................................45
6.8
Clinical Supplies Disclosure................................................................................45
7
DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL............................................................................................................46
7.1
Discontinuation of Study Intervention...............................................................46
7.2
Participant Withdrawal From the Study...........................................................47
7.3
Lost to Follow-up .................................................................................................47
8
STUDY ASSESSMENTS AND PROCEDURES ........................................................47
8.1
Administrative and General Procedures ...........................................................48
8.1.1
Informed Consent.........................................................................................48
8.1.1.1
General Informed Consent.................................................................48
8.1.1.2
Consent and Collection of Specimens for Future Biomedical 
Research.............................................................................................49
8.1.2
Inclusion/Exclusion Criteria ........................................................................49
8.1.3
Participant Identification Card.....................................................................49
8.1.4
Medical History ...........................................................................................50
8.1.5
Prior and Concomitant Medications Review ...............................................50
8.1.5.1
Prior Medications...............................................................................50
8.1.5.2
Concomitant Medications ..................................................................50
8.1.6
Assignment of Screening Number...............................................................50
8.1.7
Assignment of Treatment/Randomization Number .....................................51
8.1.8
Study Intervention Administration ..............................................................51
8.1.8.1
Timing of Dose Administration.........................................................52
8.1.9
Electronic Vaccination Report Card ............................................................52
8.1.10
Telephone Contact Guide for Day 15 Post Each Dose ................................53
8.1.11
Telephone Contact Questionnaire................................................................53
8.1.12
Discontinuation and Withdrawal .................................................................53
8.1.12.1
Withdrawal From Future Biomedical Research ................................53
8.1.13
Participant Blinding/Unblinding..................................................................54
8.1.14
Calibration of Equipment.............................................................................54
8.2
Immunogenicity Assessments .............................................................................55
8.2.1
Pneumococcal Electrochemiluminescence (PnECL)...................................55
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
5
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
8.2.2
Hepatitis B Enhanced Chemiluminescence (ECi) Assay.............................56
8.2.3
Rotavirus Serum IgA Enzyme-Linked Immunosorbent Assay (EIA) .........56
8.3
Safety Assessments...............................................................................................57
8.3.1
Physical Examinations.................................................................................57
8.3.2
Body Temperature Measurement.................................................................57
8.3.3
Safety Assessment and Use of the eVRC ....................................................58
8.3.4
Clinical Laboratory Assessments.................................................................58
8.4
Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events ....................................................................................58
8.4.1
Time Period and Frequency for Collecting AE, SAE, and Other Reportable 
Safety Event Information.............................................................................59
8.4.2
Method of Detecting AEs, SAEs, and Other Reportable Safety Events......60
8.4.3
Follow-up of AE, SAE, and Other Reportable Safety Event Information...61
8.4.4
Regulatory Reporting Requirements for SAE .............................................61
8.4.5
Pregnancy and Exposure During Breastfeeding ..........................................61
8.4.6
Disease-related Events and/or Disease-related Outcomes Not Qualifying as 
AEs or SAEs ................................................................................................61
8.4.7
Events of Clinical Interest (ECIs) ................................................................61
8.5
Treatment of Overdose........................................................................................61
8.6
Pharmacokinetics.................................................................................................62
8.7
Pharmacodynamics..............................................................................................62
8.8
Future Biomedical Research Sample Collection...............................................62
8.9
Planned Genetic Analysis Sample Collection ....................................................62
8.10
Biomarkers ...........................................................................................................62
8.11
Medical Resource Utilization and Health Economics.......................................62
8.12
Visit Requirements...............................................................................................62
8.12.1
Screening......................................................................................................63
8.12.2
Treatment Period/Vaccination Visits...........................................................63
8.12.3
Discontinued Participants Continuing to be Monitored in the Study ..........63
9
STATISTICAL ANALYSIS PLAN .............................................................................63
9.1
Statistical Analysis Plan Summary.....................................................................63
9.2
Responsibility for Analyses/In-house Blinding .................................................66
9.3
Hypotheses/Estimation ........................................................................................66
9.4
Analysis Endpoints...............................................................................................66
9.4.1
Immunogenicity Endpoints..........................................................................66
9.4.2
Safety Endpoints ..........................................................................................67
9.5
Analysis Populations............................................................................................68
9.5.1
Immunogenicity Analysis Populations ........................................................68
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
6
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
9.5.2
Safety Analysis Populations ........................................................................69
9.6
Statistical Methods...............................................................................................69
9.6.1
Statistical Methods for Immunogenicity Analyses ......................................69
9.6.2
Statistical Methods for Safety Analyses ......................................................72
9.6.3
Demographic and Baseline Characteristics .................................................75
9.7
Interim Analyses ..................................................................................................76
9.8
Multiplicity ...........................................................................................................76
9.9
Sample Size and Power Calculations .................................................................77
9.9.1
Sample Size and Power for Immunogenicity Analyses ...............................77
9.9.2
Sample Size and Power for Safety Analyses ...............................................78
9.10
Subgroup Analyses...............................................................................................79
9.11
Compliance (Medication Adherence).................................................................79
9.12
Extent of Exposure...............................................................................................79
10
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................80
10.1
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........80
10.1.1
Code of Conduct for Clinical Trials.............................................................80
10.1.2
Financial Disclosure.....................................................................................82
10.1.3
Data Protection.............................................................................................82
10.1.3.1
Confidentiality of Data ......................................................................83
10.1.3.2
Confidentiality of Participant Records...............................................83
10.1.3.3
Confidentiality of IRB/IEC Information............................................83
10.1.4
Committees Structure...................................................................................83
10.1.4.1
Scientific Advisory Committee..........................................................83
10.1.4.2
Executive Oversight Committee........................................................83
10.1.4.3
External Data Monitoring Committee ...............................................84
10.1.5
Publication Policy........................................................................................84
10.1.6
Compliance with Study Registration and Results Posting Requirements ...84
10.1.7
Compliance with Law, Audit, and Debarment ............................................85
10.1.8
Data Quality Assurance ...............................................................................85
10.1.9
Source Documents .......................................................................................86
10.1.10
Study and Site Closure.................................................................................86
10.2
Appendix 2: Clinical Laboratory Tests..............................................................87
10.3
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting...............................................................88
10.3.1
Definition of AE ..........................................................................................88
10.3.2
Definition of SAE ........................................................................................89
10.3.3
Additional Events Reported.........................................................................90
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
7
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.3.4
Recording AE and SAE ...............................................................................90
10.3.5
Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor93
10.4
Appendix 4: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow-up, and Reporting...........................................95
10.5
Appendix 5: Collection and Management of Specimens for Future 
Biomedical Research............................................................................................96
10.6
Appendix 6: Country-specific Requirements ..................................................101
10.7
Appendix 7: Abbreviations ...............................................................................102
11
REFERENCES.............................................................................................................104
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
8
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
LIST OF TABLES
Table 1
V114/Prevnar 13™ Dosing Schedule..............................................................32
Table 2
Study Interventions ..........................................................................................40
Table 3
Concomitant Vaccine Schedule .......................................................................44
Table 4
Recommended Injection-Site Location for Study Interventions .....................45
Table 5
Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events.......................................................................60
Table 6
Analysis Strategy for Immunogenicity Variables............................................72
Table 7
Analysis Strategy for Safety Parameters..........................................................75
Table 8
95% CIs for Varying Hypothetical IgG GMC Ratios and Varying 
Standard Deviations with 135 Evaluable Participants in Each 
Vaccination Group...........................................................................................77
Table 9
Differences in Incidence of Adverse Event Rates between the 2 
Vaccination Groups That Can be Detected With an ~80% Probability 
(Assuming 2-sided 5% alpha level with 180 Participants in each 
Group)..............................................................................................................79
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
9
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
LIST OF FIGURES
Figure 1
V114-027 Study Design...................................................................................15
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
10
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
1
PROTOCOL SUMMARY
1.1
Synopsis
Protocol Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the 
Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and 
Immunogenicity in Healthy Infants (PNEU-DIRECTION)
Short Title: Safety and Immunogenicity of the Interchangeability between V114 and Prevnar 
13™ in Healthy Infants
Acronym: PNEUmococcal Conjugate Vaccine Trials: V114-027 (PNEU-DIRECTION)
Hypotheses, Objectives, and Endpoints:
The following hypotheses, objectives and endpoints will be evaluated in healthy infants 
administered V114 or Prevnar 13™ in 1 of 5 intervention groups:
Group 1: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →Prevnar 13™
Group 2: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →V114
Group 3: Prevnar 13™ →Prevnar 13™ → V114 →V114
Group 4: Prevnar 13™ →V114 →V114 →V114
Group 5: V114 →V114 →V114 →V114
Primary Objectives
Primary Endpoints
- Objective: To evaluate the safety and 
tolerability of complete V114 (Group 5) and 
mixed Prevnar 13™/V114 dosing schedules 
(Groups 2, 3, and 4) compared with a complete 
dosing schedule of Prevnar 13™ (Group 1) 
with respect to the proportion of participants 
with adverse events (AEs).
Following any vaccination with V114 or 
Prevnar 13™:
- Solicited injection-site AEs from Day 1 
through Day 14 postvaccination
- Solicited systemic AEs from Day 1 through 
Day 14 postvaccination
- Vaccine-related serious adverse events 
(SAEs) through completion of study 
participation
- Objective: To evaluate the anti-pneumococcal 
polysaccharide (PnPs) serotype-specific 
Immunoglobulin G (IgG) Geometric Mean 
Concentrations (GMCs) at 30 days following 
Dose 4 for participants administered mixed 
dosing schedules of Prevnar 13™/V114 
(Groups 2, 3, and 4) compared with 
participants administered a complete dosing 
schedule of Prevnar 13™ (Group 1).
- Anti-PnPs serotype-specific IgG responses 
for the 13 shared serotypes contained in V114 
and Prevnar 13™ at 30 days postdose 4 (PD4)
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
11
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Secondary Objectives
Secondary Endpoints
- Objective: To compare the proportion of 
participants with anti-hepatitis B surface 
antigen (HBsAg) concentration ≥10 mIU/mL 
at 30 days following Dose 3 for participants 
administered a complete primary infant series 
dosing schedule of V114 (Group 5) 
concomitantly with RECOMBIVAX HB™ 
versus participants administered a complete 
primary infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) concomitantly 
with RECOMBIVAX HB™.
Hypothesis (H1): RECOMBIVAX HB™
administered concomitantly with V114 is non-
inferior to RECOMBIVAX HB™ administered 
concomitantly with Prevnar 13™ as measured 
by the proportion of participants with anti-
HBsAg concentration ≥10 mIU/mL at 30 days 
following Dose 3.
(the statistical criterion for non-inferiority 
requires the lower bound of the 2-sided 95% 
CI of the difference in proportions of 
participants with anti-HBsAg concentration≥10 
mIU/mL [V114 minus Prevnar 13™] to be 
greater than -0.10)
- Anti-HBsAg response at 30 days postdose 3 
(PD3) of V114 or Prevnar 13™
- Objective: To compare the anti-rotavirus 
Immunoglobulin A (IgA) Geometric Mean 
Titer (GMT) at 30 days following Dose 3 for 
participants administered a complete primary 
infant series dosing schedule of V114 (Group 
5) concomitantly with RotaTeq™ versus 
participants administered a complete primary 
infant series dosing schedule of Prevnar 13™ 
(Groups 1 and 2) concomitantly with 
RotaTeq™.
Hypothesis (H2): RotaTeq™ administered 
concomitantly with V114 is non-inferior to 
RotaTeq™administered concomitantly with 
Prevnar 13™ as measured by anti-rotavirus 
IgA GMT at 30 days following Dose 3.
(the statistical criterion for non-inferiority 
requires the lower bound of the 2-sided 95% 
CI of the anti-rotavirus IgA GMT ratio 
- Anti-rotavirus IgA response at 30 days PD3 
of V114 or Prevnar 13™
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
12
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
[V114/Prevnar 13™] to be greater than 0.50)
- Objectives: To evaluate the anti-PnPs 
serotype-specific IgG GMCs and the anti-PnPs 
serotype-specific IgG response rates 
(proportion of participants meeting serotype-
specific IgG threshold value of ≥0.35 μg/mL) 
at 30 days following Dose 3 separately for each 
vaccination group (Groups 1, 2, 3, 4, and 5).
- Anti-PnPs serotype-specific IgG responses 
for the 15 serotypes contained in V114 at 30 
days PD3
- Objective: To evaluate the anti-PnPs 
serotype-specific IgG GMCs at 30 days 
following Dose 4 for participants administered 
a complete dosing schedule of V114 (Group 5) 
compared with participants administered a 
complete dosing schedule of Prevnar 13™ 
(Group 1).
- Anti-PnPs serotype-specific IgG responses 
for the 13 shared serotypes contained in V114 
and Prevnar 13™ at 30 days PD4
Overall Design:
Study Phase
Phase 3
Primary Purpose
Prevention
Indication
Pneumococcal disease
Population
Healthy infants
Study Type
Interventional
Intervention Model
Parallel
This is a multi-site study.
Type of Control
Active control without placebo
Study Blinding
Double-blind
Masking
Participant
Care Provider
Investigator
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
13
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Estimated Duration of Study
The Sponsor estimates that the study will require 
approximately 25 months from the time that written 
informed consent is provided for the first participant until the 
last participant’s last study-related telephone call or visit.
For purposes of analysis and reporting, the overall study 
ends when the Sponsor receives the last laboratory result or 
at the time of final contact with the last participant, 
whichever comes last.
Number of Participants:
Approximately 900 participants will be randomized, with approximately 180 participants in each 
intervention group.
Intervention Groups and Duration:
Intervention 
Groups
Intervention 
Group Name
Vaccine
Dose 
Strength
Dose 
Frequency
Route 
of 
Admin.
Vaccination 
Regimen
Use
1
Prevnar 13™
Refer to 
product 
labeling
4 doses
IM
Single dose at Visits 
1, 2, 3, and 5 (~2, 4, 
6, and 12 to 15 
months of age, 
respectively)
Experimental
2
Prevnar 13™
Refer to 
product 
labeling
3 doses
IM
Single dose at Visits 
1, 2, and 3 (~2, 4, 
and 6 months of age, 
respectively)
Experimental
V114
Refer to 
IB
Single dose
IM
Single dose at Visit 5 
(~12 to 15 months of 
age)
Experimental
3
Prevnar 13™
Refer to 
product 
labeling
2 doses
IM
Single dose at Visits 
1 and 2 (~2 and 4 
months of age, 
respectively)
Experimental
V114
Refer to 
IB
2 doses
IM
Single dose at Visits 
3 and 5 (~6 and 12 to 
15 months of age, 
respectively)
Experimental
4
Prevnar 13™
Refer to 
product 
labeling
Single dose
IM
Single dose at Visit 1 
(~2 months of age)
Experimental
V114
Refer to 
IB
3 doses
IM
Single dose at Visits 
2, 3, and 5 (~4, 6, 
and 12 to 15 months 
of age, respectively)
Experimental
5
V114
Refer to 
IB
4 doses
IM
Single dose at Visits 
1, 2, 3, and 5 (~2, 4, 
6, and 12 to 15 
months of age, 
respectively)
Experimental
IB = Investigator’s Brochure; IM = intramuscular
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
14
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Total 
Number
5 intervention groups
Duration of 
Participation
Each participant will participate in the study for approximately 16 to 20
months from the time the participant’s legally acceptable representative
signs the Informed Consent Form (ICF) through the final contact.
Study Governance Committees:
Steering Committee
No
Executive Oversight Committee
Yes
Data Monitoring Committee
Yes
Clinical Adjudication Committee
No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers: Yes
A list of abbreviations used in this document can be found in Appendix 7.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
15
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
1.2
Schema
The key components of the study design are depicted in Figure 1.
Figure 1
V114-027 Study Design
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
16
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
1.3
Schedule of Activities (SoA)
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Administrative Procedures
Screening Procedures
Informed Consent
X
Consent must be obtained 
before any study 
procedures.
Informed Consent for Future
Biomedical Research
X
Consent for future 
biomedical research 
samples must be obtained 
before the collection of 
buccal swab DNA 
samples.
Assignment of Screening 
Number
X
Participant Identification Card
X
Inclusion/Exclusion Criteria
X
Medical History
X
Post-Enrollment Procedures
Assignment of Randomization 
Number
X
Prior/Concomitant Medication 
and Non-Study Vaccination 
Review
X
X
X
X
X
X
X
X
X
X
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
17
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
V114 or Prevnar 13™ 
Administration (Blinded)
X
X
X
X
Before vaccine 
administration, the 
investigator (or designee) 
must review medical 
history to ensure that the 
participant has no new 
contraindication to the 
vaccine(s) scheduled to be 
given. This information 
should be documented in 
the participant’s chart. 
At Visits 1, 2, 3, and 5, 
participants will receive 
either a single dose of 
V114 or Prevnar 13™.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
18
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open-label)

RotaTeq™

Pentacel™

RECOMBIVAX HB™
X
X*
X
Before vaccine 
administration, the 
investigator (or designee) 
must review medical 
history to ensure that the 
participant has no new 
contraindication to the 
vaccine(s) scheduled to be 
given. This information 
should be documented in 
the participant’s chart.
All participants will 
receive licensed 
concomitant vaccines 
according to the 
recommended schedule by 
the US ACIP. Non-US 
countries participating in 
this study must follow the 
US vaccination schedule.
See Section 6.5 for details 
on concomitant vaccines.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
19
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open-label), 
continued

RotaTeq™

Pentacel™

RECOMBIVAX HB™
X
X*
X
RotaTeq™ is 
administered orally and 
should be given before 
V114 or Prevnar 13™and 
other injectable 
concomitant vaccines.
Other injectable vaccines 
administered 
concomitantly should be 
given after V114 or 
Prevnar 13™.
*For participants who 
received the first dose of 
hepatitis B vaccine before
enrollment, 
RECOMBIVAX HB™
will be administered at ~2 
and 6 months of age and 
not at ~4 months of age. 
The receipt of hepatitis B 
vaccine at birth needs to 
be reviewed and 
documented in the 
participant’s chart.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
20
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open-label)

HIBERIX™

M-M-R™ II 

VARIVAX™
X
Before vaccine 
administration, the 
investigator (or designee) 
must review medical 
history to ensure that the 
participant has no new 
contraindication to the 
vaccine(s) scheduled to be 
given. This information 
should be documented in 
the participant’s chart.
All participants will 
receive licensed 
concomitant vaccines 
according to the 
recommended schedule by 
the US ACIP. Sites in 
non-US countries 
participating in the study 
must follow the US 
vaccination schedule. See 
Section 6.5 for details on 
concomitant vaccines.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
21
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Concomitant Vaccine 
Administration (Open-label), 
continued

HIBERIX™

M-M-R™ II 

VARIVAX™
X
Other pediatric injectable 
vaccines administered 
concomitantly should be 
given after V114 or 
Prevnar 13™.
Provide eVRC
X
Participants will be 
provided an eVRC at 
Visit 1 to record AEs,
body temperature 
measurements, 
concomitant medications, 
and non-study 
vaccinations. Instructions 
for using the eVRC will 
be reviewed with the 
participant’s legally 
acceptable representative.
Review eVRC Data with 
Participant’s Legally 
Acceptable Representative
X
X
X
X
X
X
X
X
X
See Section 8.1.10 for 
details.
Complete the Telephone 
Contact Questionnaire
X
The Telephone Contact 
Questionnaire will be 
provided by the Sponsor.
Collect eVRC from 
Participant
X
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
22
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Safety Procedures
Complete Physical 
Examination
X
To be performed by the 
investigator or medically 
qualified designee before 
vaccine is administered.
Targeted Physical 
Examination
X
X
X
To be performed by the 
investigator or medically 
qualified designee before 
vaccine is administered.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
23
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Body Temperature 
Measurement
X
X
X
X
Each participant’s body 
temperature must be taken 
before vaccination. 
Participants who have 
febrile illness (rectal 
temperature ≥38.1°C 
[≥100.5°F] or axillary 
temperature ≥37.8°C 
[≥100.0°F]) occurring at 
or within 72 hours of 
Visits 1, 2, 3 and 5 must 
be rescheduled.
Participant’s legally 
acceptable representative
will record a rectal 
temperature on the eVRC 
from Days 1 through 7 
following each 
vaccination and Days 8 
through 14 (if fever is 
suspected).
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
24
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
30-Minute Postvaccination 
Observation Period
X
X
X
X
To be performed by 
blinded study site 
personnel only.
AE Monitoring
X
X
X
X
X
X
X
X
X
X
X
AEs (serious and non-
serious) are to be reported 
from Days 1 through 14 
following each 
vaccination. SAEs and 
deaths are to be reported 
throughout the duration of 
an individual’s study 
participation.
Immunogenicity Procedures
Serum for Immunogenicity 
Assays (Including Retention 
Serum)
X
X
X
Blood samples must be 
collected before 
vaccination. 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114 
25
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Period
Intervention
Follow-up
Comments
Visit Number:
1
TC
2
TC
3
TC
4
5
TC
6
TC
Scheduled Time:
Age: ~2 
months
Dose 1
Day 
15 
after 
Dose 
1
Age: ~4 
months
Dose 2
Day 
15 
after 
Dose
2
Age: ~6 
months
Dose 3
Day 
15 
after 
Dose
3
~1 
month 
after 
Dose 
3
Age: ~12 
to 15 
months
Dose 4
Day 
15 
after 
Dose 
4
~1 
month 
after 
Dose 4
~6 
months 
after 
Dose 4
Visit Windowa:
≥42 
days of 
age to 
≤90 
days of 
age
Day 
15 to 
Day 
19
Post
dose
1
4 months 
of age to 
1 day 
prior to 5 
months of 
age
Day 
15 to 
Day 
19
Post
dose
2
6 months 
of age to 
1 day 
prior to 7 
months of 
age
Day 
15 to 
Day 
19
Post
dose
3
Day 
28 to
Day 
42 
Post
dose 3
12 months 
of age to 1 
day prior 
to 16 
months of 
age
Day 
15 to 
Day 
19
Post
dose
4
Day 28 
to Day 
42 Post
dose 4
Day 
166 to 
Day 
194 
Post
dose 4
Future Biomedical Research
Collect Buccal Swabs for 
Future Biomedical Research
X
Buccal swab DNA 
samples for analysis 
should be obtained prior 
to the vaccination at 
Visit 1, on randomized 
participants only, or at a 
later date as soon as the 
informed consent is 
obtained.
a
For calculating the visit windows, the day of vaccination is considered Day 1. To calculate visit windows for subsequent vaccinations, confirm subject date of birth and ensure 
the age of the subject will fall within the appropriate age range for each study visit.
ACIP = Advisory Committee on Immunization Practices; AE = adverse event; DNA = deoxyribonucleic acid; eVRC = electronic Vaccination Report Card; SAE = serious adverse 
event; TC = telephone contact; US = United States
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
26
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
2
INTRODUCTION
Merck Sharp & Dohme Corp. (MSD) is developing an investigational 15-valent 
pneumococcal conjugate vaccine (PCV) (referred to as V114) for the prevention of 
pneumococcal disease caused by the serotypes in the vaccine. V114 contains the 13 serotypes 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in the licensed vaccine 
Prevnar 13™(pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein], 
Wyeth Pharmaceuticals, a subsidiary of Pfizer, Inc., Philadelphia, PA), plus 2 additional 
serotypes (22F, 33F).
2.1
Study Rationale
Despite the availability of pneumococcal conjugate vaccines (PCVs), pneumococcal disease
remains a concern as non-vaccine serotypes began to appear in increasing frequency in 
invasive pneumococcal disease (IPD) isolates. Given the importance of pneumococcal
disease worldwide, the evolving serotype distribution, and the value of multiple suppliers to 
strengthen global supply, there is a continued need to develop new PCVs with expanded 
serotype coverage. V114 includes 2 key additional serotypes compared with Prevnar 13™
and will address an unmet medical and public health need for a PCV with expanded 
coverage. 
This clinical study, to be conducted in healthy infants approximately 2 months of age (42 to 
90 days of age), is part of a Phase 3 pediatric clinical program to support an initial 
registration of V114 for use in healthy infants and children for the prevention of 
pneumococcal disease caused by the 13 pneumococcal serotypes contained in Prevnar 13™
and 2 additional unique serotypes (22F and 33F) in V114.  
The purpose of this study is to describe the safety and immunogenicity of a 4-dose schedule 
(3 infant primary series followed by 1 toddler dose) of PCV when switching from 
Prevnar 13™ to V114 at Doses 2, 3, or 4 during the immunization schedule.
Currently available licensed PCVs have not shown any clinically relevant interference when 
administered concomitantly with other pediatric vaccines. With the exception of some 
countries/regions (eg, Italy and Spain where PCVs are not given simultaneously with 
vaccines to prevent influenza or meningitis), licensed PCVs are recommended to be given at 
the same time as other recommended pediatric vaccines. The concomitant administration of 
V114 with recommended pediatric vaccines will be evaluated as part of the Phase 3 pediatric
clinical program. This study will evaluate the concomitant administration of V114 and the 
licensed pediatric vaccines, RECOMBIVAX HB™ and RotaTeq™.
2.2
Background
2.2.1
V114 and Pneumococcal Disease
Refer to the Investigator’s Brochure (IB) for V114 for detailed background, including 
information on pneumococcal disease burden.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
27
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Streptococcus pneumoniae remains a significant cause of disease worldwide, with clinical 
manifestations including meningitis, sepsis, pneumonia, sinusitis, and otitis media.
Currently, many countries worldwide have incorporated licensed PCVs (eg, Prevnar 13™ 
and/or Synflorix™ [pneumococcal polysaccharide conjugate vaccine [adsorbed], 
GlaxoSmithKline Biologicals S.A, Rixensart, Belgium]) into their infant immunization 
programs. Prevnar™was first licensed in 2000 and later replaced by Prevnar 13™ in 2009 
(European Union) and 2010 (United States). Synflorix™ was licensed in the European Union 
in 2009. Although Prevnar 13™is indicated for children and adults, Synflorix™ is only 
indicated for children up to 5 years of age. Widespread use of PCVs have reduced the burden 
of pneumococcal disease due to the serotypes contained in the vaccines in children who 
received the vaccines, as well as unvaccinated individuals through herd protection [Centers 
for Disease Control and Prevention 2008] [Ruckinger, S., et al 2009] [Farrell, D. J, et al 
2007] [Pilishvili, Tamara, et al 2010] [Lexau, C. A., et al 2005] [Metlay, J. P., et al 2006] 
[Whitney, Cynthia G., et al 2003] [Moore, M. R., et al 2015] [Lepoutre, A., et al 2015] 
[Weiss, S., et al 2015] [Martinelli, D., et al 2014] [Guevara, M., et al 2016] [Waight, P. A., et 
al 2015] [Jokinen, J., et al 2015] [Palmu, A. A., et al 2015] [Wagenvoort, G. H., et al 2016]. 
Despite this, an increase in the burden of invasive pneumococcal disease (IPD) caused by 
serotypes not contained in currently available vaccines has been observed.
V114 contains all the pneumococcal serotypes contained in Prevnar 13™plus 2 additional 
serotypes (22F, 33F). The selection of 22F and 33F was primarily based on the emergence of 
these 2 serotypes as important causes of invasive pneumococcal disease in the era of 
Prevnar™ and Prevnar 13™. Approximately 4 years after inclusion of Prevnar™in the US
infant immunization schedule, serotypes 22F and 33F accounted for approximately 13% of 
IPD cases in children <5 years of age (incidence rate of IPD due to 22F and 33F of 3.1 cases 
per 100,000 person-years [PY]), in contrast to 1.3% of IPD cases in the pre-Prevnar™era 
(incidence rate of IPD due to 22F and 33F of 1.2 cases per 100,000 PY) [Hicks, L. A., et al 
2007]. By 2013, both 22F and 33F were among the leading serotypes causing IPD beyond 
those already included in Prevnar 13™, accounting for approximately 21% of all IPD in 
children <5 years of age in the US [Moore, M. R., et al 2015]. 
The additional serotypes contained in V114 will provide broader coverage against the leading 
serotypes associated with pneumococcal disease worldwide. V114 is designed to meet 
continuing medical and public health needs for PCVs globally, as well as address the 
emergence of pneumococcal disease caused by serotypes not contained in currently licensed 
PCVs.
2.2.2
Preclinical and Clinical Studies
Refer to the IB for information on completed preclinical and clinical studies conducted with 
V114.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
28
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
2.2.3
Information on Other Study-related Therapy
Refer to approved labeling for detailed background information on Prevnar 13™and other 
licensed pediatric vaccines administered concomitantly.
Prevnar 13™ contains the 7 pneumococcal serotypes included in Prevnar™ (4, 6B, 9V, 14, 
18C, 19F, 23F) plus 6 additional serotypes (1, 3, 5, 6A, 7F, and 19A).
Prevnar™ and Prevnar 13™ are also known as Prevenar™ and Prevenar 13™ in many 
countries outside of the US; these vaccines will be referred to as Prevnar™ and Prevnar 13™ 
throughout this document.
Licensed pediatric vaccines will be provided and administered concomitantly according to 
the recommended schedule by the US ACIP (Table 3). Note: Non-US countries participating 
in the study must follow the US recommended pediatric vaccination schedule.
2.3
Benefit/Risk Assessment
It cannot be guaranteed that participants in clinical studies will directly benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safety and efficacy of an investigational medicine.
Approximately 20% of participants will receive 4 doses of Prevnar 13™, the standard of 
care, as the active comparator in this study. Approximately 20% of participants will receive 
4 doses of V114 and 60% of participants will receive 4 doses of mixed V114 and Prevnar 13 
dosing schedules. V114 is expected to provide comparable immune responses and safety 
profile to Prevnar 13™ for the shared pneumococcal serotypes while providing additional 
coverage for the 2 serotypes (22F and 33F) unique to V114. It is unknown if the 
investigational V114 will have the same benefit/risk profile as Prevnar 13™.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and Informed Consent Form (ICF).
3
HYPOTHESIS, OBJECTIVES, AND ENDPOINTS
The following hypotheses, objectives and endpoints will be evaluated in healthy infants 
administered V114 or Prevnar 13™ in 1 of 5 intervention groups:
Group 1: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →Prevnar 13™
Group 2: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →V114
Group 3: Prevnar 13™ →Prevnar 13™ → V114 →V114
Group 4: Prevnar 13™ →V114 →V114 →V114
Group 5: V114 →V114 →V114 →V114
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
29
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Objectives
Endpoints
Primary
•
Objective: To evaluate the safety and 
tolerability of complete V114 (Group 5)
and mixed Prevnar 13™/V114 dosing 
schedules (Groups 2, 3, and 4) compared
with a complete dosing schedule of 
Prevnar 13™(Group 1) with respect to 
the proportion of participants with 
adverse events (AEs).
Following any vaccination with V114 or 
Prevnar 13™:
•
Solicited injection-site AEs from Day 1 
through Day 14 postvaccination
•
Solicited systemic AEs from Day 1 
through Day 14 postvaccination
•
Vaccine-related serious adverse events 
(SAEs) through completion of study
participation
•
Objective: To evaluate the anti-
pneumococcal polysaccharide (PnPs) 
serotype-specific Immunoglobulin G 
(IgG) Geometric Mean Concentrations 
(GMCs) at 30 days following Dose 4 for 
participants administered mixed dosing 
schedules of Prevnar 13™/V114 (Groups 
2, 3, and 4) compared with participants 
administered a complete dosing schedule
of Prevnar 13™(Group 1).
•
Anti-PnPs serotype-specific IgG 
responses for the 13 shared serotypes
contained in V114 and Prevnar 13™at 
30 days postdose 4 (PD4)
Secondary

Objective: To compare the proportion of 
participants with anti-hepatitis B surface 
antigen (HBsAg) concentration ≥10 
mIU/mL at 30 days following Dose 3 for 
participants administered a complete 
primary infant series dosing schedule of 
V114 (Group 5) concomitantly with 
RECOMBIVAX HB™ versus 
participants administered a complete 
primary infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) 
concomitantly with RECOMBIVAX 
HB™.
Hypothesis (H1): RECOMBIVAX HB™ 
administered concomitantly with V114 is 
non-inferior to RECOMBIVAX HB™ 
administered concomitantly with 

Anti-HBsAg response at 30 days 
postdose 3 (PD3) of V114 or 
Prevnar 13™
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
30
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Prevnar 13™ as measured by the 
proportion of participants with anti-
HBsAg concentration ≥10 mIU/mL at 30 
days following Dose 3.
(the statistical criterion for non-inferiority 
requires the lower bound of the 2-sided 95% 
CI of the difference in proportions of 
participants with anti-HBsAg 
concentration≥10 mIU/mL [V114 minus 
Prevnar 13™] to be greater than -0.10)
•
Objective: To compare the anti-rotavirus 
Immunoglobulin A (IgA) Geometric 
Mean Titer (GMT) at 30 days following 
Dose 3 for participants administered a 
complete primary infant series dosing 
schedule of V114 (Group 5) 
concomitantly with RotaTeq™ versus 
participants administered a complete 
primary infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) 
concomitantly with RotaTeq™.
Hypothesis (H2): RotaTeq™ 
administered concomitantly with V114 is 
non-inferior to RotaTeq™administered 
concomitantly with Prevnar 13™as 
measured by anti-rotavirus IgA GMT at 
30 days following Dose 3.
(the statistical criterion for non-inferiority 
requires the lower bound of the 2-sided 95% 
CI of the anti-rotavirus IgA GMT ratio 
[V114/Prevnar 13™] to be greater than 0.50)

Anti-rotavirus IgA response at 30 days 
PD3 of V114 or Prevnar 13™

Objectives: To evaluate the anti-PnPs 
serotype-specific IgG GMCs and the anti-
PnPs serotype-specific IgG response rates 
(proportion of participants meeting 
serotype-specific IgG threshold value of 
≥0.35 μg/mL) at 30 days following 
Dose 3 separately for each vaccination 
group (Groups 1, 2, 3, 4, and 5).
•
Anti-PnPs serotype-specific IgG 
responses for the 15 serotypes contained 
in V114 at 30 days PD3
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
31
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
•
Objective: To evaluate the anti-PnPs 
serotype-specific IgG GMCs at 30 days 
following Dose 4 for participants 
administered a complete dosing schedule 
of V114 (Group 5) compared with 
participants administered a complete 
dosing schedule of Prevnar 13™(Group 
1).
•
Anti-PnPs serotype-specific IgG 
responses for the 13 shared serotypes
contained in V114 and Prevnar 13™at 
30 days PD4
Tertiary/Exploratory
•
Objective: To evaluate the anti-PnPs 
serotype-specific IgG GMCs prior to 
Dose 4 separately for each vaccination 
group (Groups 1, 2, 3, 4, and 5).
•
Anti-PnPs serotype-specific IgG 
responses for the 15 serotypes contained 
in V114 prior to Dose 4 (pre-dose 4)
•
Objective: To evaluate the anti-HBsAg 
GMCs at 30 days following Dose 3 for 
participants administered a complete 
primary infant series dosing schedule of 
V114 (Group 5) concomitantly with 
RECOMBIVAX HB™ versus 
participants administered a complete 
primary infant series dosing schedule of 
Prevnar 13™ (Groups 1 and 2) 
concomitantly with 
RECOMBIVAX HB™.
•
Anti-HBsAg response at 30 days PD3 of 
V114 or Prevnar 13™
4
STUDY DESIGN
4.1
Overall Design
Approximately 900 healthy infants will be randomly assigned, in a 1:1:1:1:1 ratio, to 1 of 5 
vaccination groups (180 per group) (Table 1). Randomization will be stratified by previous 
hepatitis B vaccination status. All participants will receive other licensed pediatric vaccines 
administered concomitantly according to the recommended schedule by the US ACIP (Table 
3). Note: Non-US countries participating in the study must follow the US vaccination 
schedule.
Participants will be followed for local and systemic AEs through Day 14 following each 
vaccination with V114 or Prevnar 13™. Information for SAEs and deaths, regardless of 
whether the events are considered to be vaccine-related by the investigator, will be collected 
from the time consent is signed through completion of participation in the study. An external 
Data Monitoring Committee (DMC) will conduct a periodic review of safety and tolerability 
data for the V114 Phase 3 pediatric program. A description of the structure, function, and 
guidelines for decision-making by the DMC, along with the timing and content of the safety 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
32
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
reviews will be outlined in the DMC charter. Information regarding the composition of the 
DMC is provided in Appendix 1.
Blood samples for immunogenicity assays will be drawn at 3 timepoints: (1) 30 days 
Postdose 3, (2) immediately prior to Dose 4, and (3) 30 days Postdose 4.
After completion of immunogenicity testing (including electrochemiluminescence [ECL]
testing to measure V114 or Prevnar 13™-induced pneumococcal-specific immune responses, 
anti-HBsAg concentration measurement, and anti-rotavirus IgA measurement), serum 
samples will be stored to conduct any additional study-related testing as required by 
regulatory agencies or the Sponsor. For randomized study participants who provided consent 
for Future Biomedical Research, leftover sera from the study may be used for the 
development and/or validation of pneumococcal assays after completion of all study-related 
immunogenicity testing.
Specific procedures to be performed during the study, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
Table 1
V114/Prevnar 13™ Dosing Schedule
Intervention 
Group Name
Dose 1 (Visit 1, ~2 
months of age)
Dose 2 (Visit 2, ~4 
months of age)
Dose 3 (Visit 3, ~6 
months of age)
Dose 4 (Visit 5, ~12 to 
15 months of age)
≥42 days of age to 
≤90 days of age
4 months of age to 
1 day prior to 
5 months of age
6 months of age to 
1 day prior to 
7 months of age
12 months of age to 
1 day prior to 
16 months of age
Group 1
Prevnar 13™
Prevnar 13™
Prevnar 13™
Prevnar 13™
Group 2
Prevnar 13™
Prevnar 13™
Prevnar 13™
V114
Group 3
Prevnar 13™
Prevnar 13™
V114
V114
Group 4
Prevnar 13™
V114
V114
V114
Group 5
V114
V114
V114
V114
4.2
Scientific Rationale for Study Design
This study will be conducted in healthy infants approximately 2 months of age (42 to 90 days 
of age). These infants are at increased risk for pneumococcal disease and its associated 
morbidity and mortality [Drijkoningen, J. J 2014]. In addition, the enrollment of infants is 
intended to assess safety, tolerability, and immunogenicity in a population that is 
representative of children receiving licensed PCVs and the recommended concomitant 
pediatric vaccines in the US and non-US countries.
This study is designed to evaluate the safety and immunogenicity of mixed PCV regimens in 
which the pneumococcal immunization series is initiated with Prevnar 13™and is changed 
to V114 at Dose 2, 3 or 4. Data from this study will support the safety and immunogenicity 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
33
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
of switching to V114 at any time during the immunization series in settings where 
Prevnar 13™ is already widely used.
The safety and immunogenicity endpoints are consistent with previous studies evaluating the
interchangeability of PCVs and immunogenicity of hepatitis B and rotavirus vaccines when 
PCVs are given concomitantly. Data from this study will also contribute to the overall safety 
database and immunogenicity profile of V114 to support initial licensure in infants.
4.2.1
Rationale for Endpoints
4.2.1.1
Immunogenicity Endpoints
Previous studies have evaluated the interchangeability of PCVs [Truck, J., et al 2016] 
[Ciapponi, A., et al 2016]. These studies evaluated the immune responses and reactogenicity 
in infants primed with Prevnar 13™and boosted with Synflorix™(as compared with a 
Prevnar 13™booster) and in infants primed with Prevnar™and boosted with Prevnar 13™. 
The primary immunogenicity endpoint of these interchangeability studies were assessed 1 
month after the administration of the last scheduled dose of the PCVs.
This study will evaluate the safety, tolerability, and immunogenicity of the interchangeability 
between V114 and Prevnar 13™ in participants administered mixed dosing schedules of 
Prevnar 13™and V114 (Groups 2, 3, and 4) compared with participants administered a 
complete dosing schedule of Prevnar 13™ (Group 1).
Sera from participants will be used to measure vaccine-induced anti-PnPs serotype-specific 
IgG for the 13 shared serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 
contained in V114 and Prevnar 13™ at 30 days after Dose 4. The primary interchangeability 
immunogenicity endpoint will be assessed after completion of the full PCV regimen. Anti-
PnPs serotype-specific IgG responses will also be measured at 30 days following completion 
of the primary infant series and prior to Dose 4 to evaluate the anamnestic antibody 
responses and the persistence of protective immunity.
Sera from participants will also be used to measure anti HBsAg concentration using the 
hepatitis B enhanced chemiluminescence (ECi) assay. An anti-HBsAg concentration of 
≥10 mIU/mL measured 1 to 3 months after administration of the last dose of the primary 
3-dose vaccination series is considered a reliable marker of protection against hepatitis B 
infection [Van Damme, P. 2016]. In this study, infants will receive a total of 3 hepatitis B 
vaccinations (2, 4 and 6 months). For those participants who received the first dose of 
hepatitis B vaccine prior to enrollment in the study, hepatitis B vaccine will be administered 
at 2 and 6 months of age and not at 4 months. Because antibody responses and GMTs may be 
slightly higher when hepatitis B vaccination is initiated after 1 month of life [Schillie, S. F. 
2013], randomization in this study will be stratified by previous hepatitis B vaccination status 
before enrollment.
Sera from participants will also be used to measure anti-rotavirus IgA using the enzyme-
linked immunosorbent assay (EIA). Serum anti-rotavirus IgA is a marker of protection 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
34
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
against rotavirus infection and moderate-to-severe diarrhea [Velázquez, F. R., et al 2000]. 
Following rotavirus vaccination, there is a correlation between serum anti-rotavirus IgA 
GMT ratios following Dose 3 and protective immunity at the population level [Liu, G. F., et 
al 2017].
Details on the immunogenicity endpoints evaluated in this study can be found in 
Section 9.4.1.
4.2.1.2
Safety Endpoints
The safety endpoints evaluated in this study were selected based on the product’s safety 
profile demonstrated in previous studies, published data from marketed PCVs, and feedback 
received from regulatory agencies during product development. The electronic Vaccination 
Report Card (eVRC) used to record AEs during the postvaccination periods, as defined in 
Section 8.1.9, was structured as recommended in the final Food and Drug Administration 
Patient Reported Outcome Guidance [U.S. Food and Drug Administration 2009].
Details on the safety endpoints evaluated in this study can be found in Section 8.3.3 and 
Section 9.4.2.
Details on AEs, including definitions and reporting requirements, can be found in 
Appendix 3.
4.2.1.3
Future Biomedical Research
The Sponsor will conduct future biomedical research on specimens for which consent was 
provided during this study. This research may include genetic analyses (DNA), gene 
expression profiling (ribonucleic acid [RNA]), proteomics, metabolomics (serum, plasma), 
and/or the measurement of other analytes, depending on which specimens are consented for 
future biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study) and will only be conducted on specimens from 
appropriately consented participants. The objective of collecting/retaining specimens for 
future biomedical research is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of this future biomedical research substudy are presented in Appendix 5.
4.2.2
Rationale for the Use of Comparator
Placebo-controlled clinical studies for new PCVs are no longer acceptable given the proven 
clinical efficacy, public health impact, and widespread use of licensed PCVs worldwide. 
Prevnar 13™is currently the most widely recommended vaccine for the prevention of 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
35
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
pneumococcal disease in infants in many countries worldwide, includes the largest number of 
serotypes, and will be used as the active comparator in this study.
Refer to approved labeling for detailed background information on Prevnar 13™.
4.3
Justification for Dose
The dose and dosing schedule of V114 is similar to that used in previous pediatric V114 
clinical studies, which demonstrated safety and comparable immune responses to those of 
Prevnar 13™. Refer to V114 IB for details on dosing schedule.
In order to support initial licensure in countries that use either the 3+1 Prevnar 13™dosing 
schedule (3 doses in the infant primary series followed by 1 toddler dose) or the 2+1 
Prevnar 13™dosing schedule (2 doses in infant primary series followed by 1 toddler dose), 
this study will use the currently approved dose and US ACIP recommended 3+1 dosing 
schedule of Prevnar 13™.
4.4
Beginning and End of Study Definition
The overall study begins when written informed consent is provided for the first participant. 
The overall study ends when the last participant completes the last study-related telephone-
call or visit, withdraws from the study, or is lost to follow-up (ie, the participant is unable to 
be contacted by the investigator).
For purposes of analysis and reporting, the overall study ends when the Sponsor receives the 
last laboratory result or at the time of final contact with the last participant, whichever comes 
last.
4.4.1
Clinical Criteria for Early Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population 
as a whole is unacceptable. In addition, further recruitment in the study or at (a) particular 
study site(s) may be stopped due to insufficient compliance with the protocol, Good Clinical 
Practice (GCP), and/or other applicable regulatory requirements, procedure-related problems 
or an unacceptably high number of discontinuations or withdrawals due to administrative 
reasons.
5
STUDY POPULATION
Healthy male and female infants approximately 2 months of age, from 42 and 90 days 
(inclusive) will be enrolled in this study.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
36
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
5.1
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
1. Participant is healthy (based on a review of medical history and physical examination)
based on the clinical judgement of the investigator.
Demographics
2. Participant is male or female infant approximately 2 months of age, from 42 days to 90
days inclusive, at the time of obtaining the informed consent.
Informed Consent
3. Participant has a legally acceptable representative who understands the study procedures, 
alternate treatments available, and risks involved with the study and voluntarily agrees to 
participate by giving written informed consent. The legally acceptable representative may 
also provide consent for future biomedical research. However, the participant may 
participate in the main study without participating in future biomedical research.
5.2
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1. Has a history of invasive pneumococcal disease (positive blood culture, positive 
cerebrospinal fluid culture, or other sterile site) or known history of other culture positive 
pneumococcal disease.
2. Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine 
(PCV), any component of the licensed pediatric vaccines to be administered 
concomitantly in the study, or any diphtheria toxoid-containing vaccine.
3. Has any contraindication to the concomitant study vaccines being administered in the 
study (concomitant vaccine contraindication details provided in the Investigator Trial File 
Binder).
4. *Had a recent febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary 
temperature ≥37.8°C [≥100.0°F]) occurring within 72 hours prior to receipt of study 
vaccine.
5. Has a known or suspected impairment of immunological function.
6. Has a history of congenital or acquired immunodeficiency.
7. Has or his/her mother has a documented human immunodeficiency virus (HIV) infection.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
37
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
8. Has or his/her mother has a documented hepatitis B surface antigen – positive test.
9. Has known or history of functional or anatomic asplenia.
10. Has failure to thrive based on the clinical judgement of the investigator.
11. Has a known coagulation disorder contraindicating intramuscular vaccination.
12. Has a history of autoimmune disease (including but not limited to systemic lupus 
erythematosus, antiphospholipid syndrome, Behcet’s disease, autoimmune thyroid 
disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or 
other autoimmune disorders).
13. Has a known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, 
acute disseminating encephalomyelitis, pervasive development disorder, and related 
disorders.
Prior/Concomitant Therapy
14. Has received a dose of any pneumococcal vaccine prior to study entry.
15. Has received >1 dose of monovalent hepatitis B vaccine or hepatitis B based combination 
vaccine prior to study entry.
16. Has received a dose of rotavirus vaccine prior to study entry.
17. *Meets one or more of the following systemic corticosteroid exclusion criteria:
a.
Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of 
prednisone or ≥20 mg/d for persons weighing >10 kg) for ≥14 consecutive days and 
has not completed this course of treatment at least 30 days prior to study 
randomization.
b. Has received systemic corticosteroids within 14 days prior to the first dose of vaccine 
at randomization.
c.
Is expected to require systemic corticosteroids within 30 days after each vaccination 
during conduct of the study.
Note: Topical, ophthalmic and inhaled steroids are permitted.
18. *Has received other licensed non-live vaccines within the 14 days before receipt of first 
dose of study vaccine.
19. *Has received a licensed live virus vaccine within the 30 days prior to receipt of first 
dose of study vaccine.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
38
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
20. Has received a blood transfusion or blood products, including immunoglobulins.
Prior/Concurrent Clinical Study Experience
21. Has participated in another clinical study of an investigational product before the 
beginning or anytime during the duration of the current clinical study. Participants
enrolled in observational studies may be included; these will be reviewed on a 
case-by-case basis for approval by the Sponsor.
Other Exclusions 
22. Has any other reason that, in the opinion of the investigator, may interfere with the 
evaluation required by the study. Reasons may include, but are not limited to, being 
unable to keep appointments or planning to relocate during the study.
23. Is or has an immediate family member (eg, parent/legal guardian or sibling) who is 
investigational site or Sponsor staff directly involved with this study.
For items with an asterisk (*), if the participant meets these exclusion criteria, Visit 1
may be rescheduled for a time when these criteria are not met.
5.3
Lifestyle Considerations
No lifestyle restrictions are required.
5.4
Screen Failures
Screen failures are defined as participants whose legally acceptable representative provides
consent to participate in the clinical study, but are not subsequently randomized in the study. 
A minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participants to meet the Consolidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria, and any 
AEs or SAEs meeting reporting requirements as outlined in the data entry guidelines.
5.5
Participant Replacement Strategy
A participant who withdraws from the study will not be replaced.
6
STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
39
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Clinical supplies (V114, Prevnar 13™, and concomitant vaccines listed in Table 3) will be 
packaged to support enrollment. Clinical supplies will be affixed with a clinical label in 
accordance with regulatory requirements.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
40
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
6.1
Study Intervention(s) Administered
The blinded study interventions to be used in this study are outlined in Table 2. Licensed pediatric vaccines will be administered 
concomitantly across all intervention groups; refer to Table 3 for dosing schedule and refer to product labeling for dose formulation, 
dose strength, dosage level, etc.
Table 2
Study Interventions
Arm 
Name
Arm Type
Intervention 
Name
Type
Dose 
Formulation
Unit Dose 
Strength(s)
Dosage 
Level(s)
Route of 
Admin
Vaccination Regimen
Use
IMP/N
IMP
Sourcing
1
Active 
Comparator
Prevnar 13™
Biological/
Vaccine
Sterile 
suspension
Refer to 
product 
labeling
0.5 mL
IM
Single dose at Visits 1, 2, 
3, and 5 (~2, 4, 6, and 12 
to 15 months of age, 
respectively)
Experimental
IMP
Central
2
Experimental
Prevnar 13™
Biological/
Vaccine
Sterile 
suspension
Refer to 
product 
labeling
0.5 mL
IM
Single dose at Visits 1, 2, 
and 3 (~2, 4, and 6 
months of age, 
respectively)
Experimental
IMP
Central
V114
Biological/
Vaccine
Sterile 
suspension
Refer to IB
0.5 mL
IM
Single dose at Visit 5 
(~12 to 15 months of age)
Experimental
IMP
Central
3
Experimental
Prevnar 13™
Biological/
Vaccine
Sterile 
suspension
Refer to 
product 
labeling
0.5 mL
IM
Single dose at Visits 1 
and 2 (~2 and 4 months 
of age, respectively)
Experimental
IMP
Central
V114
Biological/
Vaccine
Sterile 
suspension
Refer to IB
0.5 mL
IM
Single dose at Visits 3 
and 5 (~6 and 12 to 15 
months of age, 
respectively)
Experimental
IMP
Central
4
Experimental
Prevnar 13™
Biological/
Vaccine
Sterile 
suspension
Refer to 
product 
labeling
0.5 mL
IM
Single dose at Visit 1 (~2 
months of age)
Experimental
IMP
Central
V114
Biological/
Vaccine
Sterile 
suspension
Refer to IB
0.5 mL
IM
Single dose at Visits 2, 3, 
and 5 (~4, 6, and 12 to 15 
months of age, 
respectively)
Experimental
IMP
Central
5
Experimental
V114
Biological/
Vaccine
Sterile 
suspension
Refer to IB
0.5 mL
IM
Single dose at Visits 1, 2, 
3, and 5 (~2, 4, 6, and 12 
to 15 months of age, 
respectively)
Experimental
IMP
Central
Admin = administration; IB = Investigator’s Brochure; IM = intramuscular; IMP = investigational medicinal product; NIMP = non-investigational medicinal product
The definition of IMP and NIMP is based on guidance issued by the European Commission. Regional and/or country differences of the definition of IMP/NIMP may exist. In these circumstances, local 
legislation is followed.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
41
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
All supplies indicated in Table 2 will be provided per the "Sourcing" column depending upon 
local country operational requirements. Every attempt should be made to source these 
supplies from a single lot/batch number.
Refer to Section 8.1.8 for details regarding administration of the study intervention.
6.2
Preparation/Handling/Storage/Accountability
6.2.1
Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. The rationale for selection of doses to be used 
in this study is provided in Section 4.3.
6.2.2
Handling, Storage, and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and any discrepancies are 
reported and resolved before use of the study intervention.
Only participants enrolled in the study may receive study intervention, and only authorized 
site staff may supply or administer study intervention. All study interventions must be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expiry date for 
any locally purchased product (if applicable) as per local guidelines unless otherwise 
instructed by the Sponsor.
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
42
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
6.3
Measures to Minimize Bias: Randomization and Blinding
6.3.1
Intervention Assignment
Treatment allocation/randomization will occur centrally using an interactive response 
technology (IRT) system. There are 5 study intervention arms. Participants will be assigned 
randomly in a 1:1:1:1:1 ratio to the study intervention listed in Table 2.
6.3.2
Stratification
Intervention allocation/randomization will be stratified according to the following factors:

Hepatitis B vaccination status before enrollment (Yes, No)
Stratification by hepatitis B vaccination status before enrollment is relevant for this study
because the timing of the first dose of hepatitis B vaccine may have an effect on 
immunogenicity evaluation of the secondary endpoint related to concomitant administration 
of RECOMBIVAX HB™(see Section 4.2.1.1 for details).
6.3.3
Blinding
A double-blinding technique will be used. V114 and Prevnar 13™will be prepared and/or 
dispensed by an unblinded pharmacist or unblinded qualified study site personnel. The 
participant and the investigator who is involved in the clinical evaluation of the participants 
will remain blinded to the group assignments.
Because V114 and Prevnar 13™ have a different appearance, a member of the study site staff 
will be unblinded for the purposes of receiving, maintaining, preparing, and administering 
these study vaccines. Procedures for handling, preparing, and administering the unblinded 
vaccines are located in the Investigator Trial File Binder. 
In order to avoid bias, the unblinded study personnel will have no further contact with study
participants for any study-related procedures/assessments after administration of study 
vaccines, which includes all safety follow-up procedures. Additionally, blinded site 
personnel will not be present in the examination room when study vaccines are administered. 
Contact between participants and unblinded study personnel after vaccination administration 
is strictly prohibited. Blinded site personnel will be responsible for all safety and 
immunogenicity follow-up procedures after vaccine administration.
An unblinded Clinical Research Associate will monitor vaccine accountability at the study 
site. All other Sponsor personnel or delegate(s) and Merck Research Laboratories employees 
directly involved with the conduct of this study will remain blinded to the participant-level 
intervention assignment.
See Section 8.1.13 for a description of the method of unblinding a participant during the 
study should such action be warranted.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
43
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
6.4
Study Intervention Compliance
Interruptions from the protocol specified plan for V114 or Prevnar 13™ vaccination at Visits 
1, 2, 3, and 5 and concomitant vaccinations listed in Table 3 require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
6.5
Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed
during the ongoing study (see Section 5.2 for details). If there is a clinical indication for any 
medication or vaccination specifically prohibited, discontinuation from study intervention 
may be required. The investigator should discuss any questions regarding this with the 
Sponsor Clinical Director. The final decision on any supportive therapy or vaccination rests 
with the investigator and/or the participant’s primary physician. However, the decision to 
continue the participant on study intervention requires the mutual agreement of the 
investigator, the Sponsor, and the participant’s legally acceptable representative.
If a medical condition requires the use of a prohibitive steroid regimen, immunoglobulin, 
blood, or blood products during a subject's participation in this study, one of the individuals 
listed on the Sponsor Contact Information page must be notified as soon as possible. Any 
concurrent medication or medical treatment must be recorded on the appropriate eCRF. It is 
important to record the use of any analgesic or antipyretic medication that occurs on the day 
of vaccination on the eVRC and appropriate eCRF.
Other licensed pediatric vaccines will be administered concomitantly according to the 
recommended schedule (Table 3). In the US, the ACIP recommends that hepatitis B vaccine 
should be given at birth; however, guidelines for non-US counties may differ. For 
participants who received the first dose of hepatitis B vaccine before enrollment, 
RECOMBIVAX HB™ will be administered at ~2 and 6 months of age and not at ~4 months 
of age.
In addition to concomitant vaccines being provided in the study (Table 3), other non-study 
pediatric vaccines may be permitted according to local, regional, and/or country 
guidelines. If the participant is scheduled to receive any other non-study pediatric vaccine, 
the investigator should discuss this with the Sponsor Clinical Director as soon as possible.
These vaccinations should be recorded on the appropriate eCRF.
During influenza season, it is anticipated that participants 6 months of age and older may be 
given an influenza vaccine. Influenza vaccine should be administered either 7 days prior to or 
15 days after the administration of the study vaccine. 
Concomitant vaccines (oral or injectable) should be administered on the same day as V114 or 
Prevnar 13™. RotaTeq™ is administered orally and should be given before V114 or 
Prevnar 13™ and other injectable concomitant vaccines. Precautions must be taken to 
prevent choking during the administration of oral vaccines. Other pediatric injectable 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
44
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
vaccines administered concomitantly should be given after V114 or Prevnar 13™. To avoid 
any confounding results, concomitant injectable vaccines should not be administered in the 
same limb as V114 or Prevnar 13™. Recommended injection-site locations for V114 or 
Prevnar 13™ and concomitant injectable vaccines are listed in Table 4.
Documentation of which limb to use for the administration of study vaccines must be 
recorded on the appropriate eCRF. Injection-site AEs for V114 or Prevnar 13™(and not for
the concomitant vaccines) are being reported in this study; therefore, this information must 
also be recorded on the eVRC to inform the participant’s legally acceptable representative of
the appropriate limb to monitor for AEs related to the V114 or Prevnar 13™. 
No other investigational compound or device may be administered at any time during this 
study without prior approval by the Sponsor.
Table 3
Concomitant Vaccine Schedule
Vaccine Tradename a
(Generic Name)
Indication
Visit 1
(~2 months 
of age)
Visit 2
(~4 months 
of age)
Visit 3
(~6 months 
of age)
Visit 5
(~12 to 15 
months of 
age)
RotaTeq™b
(Rotavirus Vaccine, Live, 
Oral, Pentavalent)
Prevention of rotavirus 
gastroenteritis
X
X
X
Pentacel™(Diphtheria and 
Tetanus Toxoids and Acellular 
Pertussis Adsorbed, 
Inactivated Poliovirus and 
Haemophilus b Conjugate 
(Tetanus Toxoid Conjugate) 
Vaccine
Prevention of 
diphtheria, tetanus, 
pertussis, poliomyelitis, 
and invasive disease
due to Haemophilus 
influenzae type b
X
X
X
RECOMBIVAX HB™
(Hepatitis B Vaccine 
[Recombinant])
Prevention of hepatitis 
B virus infection
X
X c
X
HIBERIX™
(Haemophilus b Conjugate 
Vaccine [Tetanus Toxoid 
Conjugate])
Prevention of invasive 
disease caused by 
Haemophilus influenzae
type b
X
M-M-R™ II
(Measles, Mumps, and Rubella 
Virus Vaccine Live)
Simultaneous 
vaccination against 
measles, mumps, and 
rubella
X
VARIVAX™
(Varicella Virus Vaccine Live)
Prevention of varicella
X
a 
Tradenames for concomitant vaccines may vary depending on where clinical supplies are sourced by the Sponsor.
b
RotaTeq™ is administered orally and should be given before V114 or Prevnar 13™ and other injectable concomitant 
vaccines. 
c
For participants who received the first dose of hepatitis B vaccine before enrollment, RECOMBIVAX HB™ will be 
provided and administered concomitantly with V114 or Prevnar 13™.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
45
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Table 4
Recommended Injection-Site Location for Study Interventions
Vaccine
Recommended Injection Site
V114 or Prevnar 13™
Right thigh
Pentacel™
Left upper thigh
RECOMBIVAX HB™
Left lower thigh
M-M-R™ II
Deltoid right arm
VARIVAX™
Deltoid left arm
HIBERIX™
Left thigh
6.5.1
Rescue Medications and Supportive Care
No rescue or supportive medications are specified to be used in this study.
6.6
Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study.
6.7
Intervention After the End of the Study
There is no study-specified intervention following the end of the study.
6.8
Clinical Supplies Disclosure
This study is blinded but supplies are provided open-label; therefore, an unblinded 
pharmacist or unblinded qualified study site personnel will be used to maintain the blinding 
of study staff who are directly involved in the clinical evaluation of participants in the study. 
Study intervention identity (name, strength, or potency) is included in the label text; random 
code/disclosure envelopes or lists are not provided.
The emergency unblinding call center will use the intervention/randomization schedule for 
the study to unblind participants and to unmask study intervention identity. The emergency 
unblinding call center should only be used in cases of emergency (see Section 8.1.13). In the 
event that the emergency unblinding call center is not available for a given site in this study, 
the central electronic intervention allocation/randomization system (IRT) should be used to 
unblind participants and to unmask study intervention identity. The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
See Section 8.1.13 for a description of the method of unblinding a participant during the 
study, should such action be warranted.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
46
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
7
DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL
7.1
Discontinuation of Study Intervention
Discontinuation of study intervention does not represent withdrawal from the study.
As certain data on clinical events beyond study intervention discontinuation may be 
important to the study, they must be collected through the participant’s last scheduled follow-
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention prior to completion of the protocol-specified vaccination 
regimen will still continue to participate in the study as specified in Section 1.3, unless the 
consent is withdrawn for the participant (Section 7.2). A participant may discontinue from 
study intervention (including receipt of V114, Prevnar 13™ and concomitant vaccines 
provided in the study) but continue to participate in protocol-specified, AE-monitoring 
activities (see Section 8.12.3 for details).
Participants may discontinue study intervention at any time for any reason or be discontinued 
from the study intervention at the discretion of the investigator should any untoward effect 
occur. In addition, a participant may be discontinued from study intervention by the 
investigator or the Sponsor if study intervention is inappropriate, the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1.12.
A participant must be discontinued from study intervention but continue to be monitored in 
the study for any of the following reasons:
•
The participant’s legally acceptable representative requests to discontinue study 
intervention.
•
The participant’s treatment assignment is unblinded by the investigator, MSD subsidiary, 
or through the emergency unblinding call center.
•
The participant has a medical condition or personal circumstance which, in the opinion of 
the investigator and/or Sponsor, places the participant at unnecessary risk from continued 
administration of study intervention.
For participants who are discontinued from study intervention but continue to be monitored 
in the study, see Section 1.3 and Section 8.12.3 for those procedures to be completed at each 
specified visit.
Discontinuation from study intervention is “permanent”. Once a participant is discontinued, 
he/she shall not be allowed to restart study intervention.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
47
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
7.2
Participant Withdrawal From the Study
A participant must be withdrawn from the study if the participant’s legally acceptable 
representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study,as well as specific details regarding withdrawal from future biomedical research, are 
outlined in Section 8.1.12. The procedures to be performed should a participant repeatedly 
fail to return for scheduled visits and/or if the study site is unable to contact the participant 
are outlined in Section 7.3.
7.3
Lost to Follow-up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:
•
The site must attempt to contact the participant’s legally acceptable representative and 
reschedule the missed visit. If the participant’s legally acceptable representative is 
contacted, the participant’s legally acceptable representative should be counseled on the 
importance of maintaining the protocol-specified visit schedule.
•
The investigator or designee must make every effort to regain contact with the 
participant’s legally acceptable representative at each missed visit (eg, telephone calls 
and/or a certified letter to the participant’s legally acceptable representative last known 
mailing address or locally equivalent methods). These contact attempts should be 
documented in the participant’s medical record.
•
Note: A participant is not considered lost to follow-up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and analysis guidelines.
8
STUDY ASSESSMENTS AND PROCEDURES
•
Study procedures and their timing are summarized in the SoA.
•
Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•
The investigator is responsible for ensuring that procedures are conducted by 
appropriately qualified or trained staff. Delegation of study site personnel responsibilities 
will be documented in the Investigator Trial File Binder (or equivalent).
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
48
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
•
All study-related medical decisions must be made by an investigator who is a qualified 
physician.
•
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be utilized for screening or baseline 
purposes provided the procedure met the protocol-specified criteria and were performed 
within the time frame defined in the SoA.
•
Additional evaluations/testing may be deemed necessary by the investigator and or the 
Sponsor for reasons related to participant safety. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent, be obtained from the participant’s legally 
acceptable representative. In these cases, such evaluations/testing will be performed in 
accordance with those regulations.
Approximately 5 mL of blood will be drawn at each of Visits 4, 5, and 6 for immunogenicity 
assays. The maximum amount of blood collected from each participant over the duration of 
the study will not exceed 15 mL.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
8.1
Administrative and General Procedures
8.1.1
Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented consent, from each potential participant’s legally acceptable 
representative prior to participating in a clinical study or future biomedical research. If there 
are changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
consent is in place.
8.1.1.1
General Informed Consent
Consent must be documented on the consent form by the dated signature of the participant’s 
legally acceptable representative along with the dated signature of the person conducting the 
consent discussion.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
49
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
A copy of the signed and dated consent form should be given to the participant’s legally 
acceptable representative before the individual’s participation in the study.
The initial informed consent form, any subsequent revised written informed consent form, 
and any written information provided to the participant’s legally acceptable representative 
must receive the Institutional Review Board/Independent Ethics Committee’s (IRB/IEC’s)
approval/favorable opinion in advance of use. The participant’s legally acceptable 
representative should be informed in a timely manner if new information becomes available 
that may be relevant to the willingness for the participant to continue participation in the 
study. The communication of this information will be provided and documented via a revised 
consent form or addendum to the original consent form that captures the dated signature of
the participant’s legally acceptable representative.
Specifics about a study and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements.
8.1.1.2
Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified designee will explain the future biomedical research 
consent to the participant’s legally acceptable representative, answer all of his/her questions, 
and obtain written informed consent before performing any procedure related to the future 
biomedical research substudy. A copy of the informed consent will be given to the 
participant’s legally acceptable representative.
8.1.2
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator, who is a qualified 
physician, to ensure that the participant qualifies for the study. The investigator should 
consult with the Sponsor’s Clinical Director for any questions about participant eligibility.
If the participant meets any of the Exclusion Criteria with an asterisk (*), Visit 1 may be 
rescheduled for a time when these criteria are not met.
8.1.3
Participant Identification Card
The legally acceptable representative for each participant will be given a participant 
identification card identifying the individual as a participant in a research study. The card 
will contain study site contact information (including direct telephone numbers) to be used in 
the event of an emergency. The investigator or qualified designee will provide the legally 
acceptable representative for each participant with a participant identification card 
immediately after written informed consent is provided. At the time of intervention
allocation/randomization, site personnel will add the intervention/randomization number to 
the participant identification card.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
50
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
The participant identification card also contains contact information for the emergency 
unblinding call center so that a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
8.1.4
Medical History
A medical history will be obtained by the investigator or qualified designee before 
vaccination at Visit 1. Note: Birth weight (kg) and gestational age will be documented in the 
participant’s medical history.
8.1.5
Prior and Concomitant Medications Review
8.1.5.1
Prior Medications
The investigator or qualified designee will review and record prior vaccinations and 
medications taken by the participant within 30 days before the first dose of study vaccine at 
Visit 1. The receipt of hepatitis B vaccine at birth needs to be reviewed and documented in 
the participant’s chart.
8.1.5.2
Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the participant 
during the study.
If a medical condition requires the use of steroids, immunoglobulin, blood, or blood products 
during a subject's participation in this study, one of the individuals listed on the SPONSOR 
Contact Information page must be notified as soon as possible. Any concurrent medication or 
medical treatment must be recorded on the appropriate eCRF. 
It is important to record any analgesic or antipyretic use that occurs on the day of vaccination 
on the eVRC and appropriate eCRF. Concomitant medications taken after Visit 1 and non-
study vaccines received since Visit 1 will be recorded with the eVRC as specified in 
Section 8.3.3.
Licensed pediatric vaccines listed in Table 3 will be recorded on the appropriate eCRF. To 
avoid any confounding results, concomitant injectable vaccines should not be administered in 
the same limb as V114 or Prevnar 13™. Documentation of which limb was used for the 
administration of V114 or Prevnar 13™must be recorded on the eVRC (Section 8.3.3) and 
appropriate eCRF. Documentation of injection-site location for the concomitant injectable 
vaccines must be recorded on the appropriate eCRF.
8.1.6
Assignment of Screening Number
All consented participants will be given a unique screening number that will be used to 
identify the participant for all procedures that occur prior to randomization. Each participant 
will be assigned only 1 screening number. Screening numbers must not be re-used for 
different participants.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
51
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit. Specific details on the screening visit requirements are 
provided in Section 8.12.1.
8.1.7
Assignment of Treatment/Randomization Number
All eligible participants will be randomly allocated and will receive a 
treatment/randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment/randomization number is assigned to a participant, it can never be re-assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment/randomization number.
8.1.8
Study Intervention Administration
Unblinded study personnel not otherwise involved in the conduct of the study will prepare 
and administer the study vaccine. Procedures for handling, preparing, and administering the 
unblinded vaccines are provided in the Investigator Trial File Binder. Unblinded study 
personnel should not have contact with participants for any study-related 
procedures/assessments after administration of study vaccines, which includes all safety 
follow-up procedures.
Study vaccines should be removed from the refrigerator no more than 1 hour before 
vaccination. The time of removal and time of vaccination should be documented in the 
participant’s chart.
If the V114 is provided as a syringe: Prior to administration of study vaccine, the unblinded 
pharmacist should shake vigorously to obtain a homogenous white suspension. If white-
colored insoluble particle appears, the unblinded pharmacist should use rapid, horizontal 
hand shaking for 5 to 10 seconds while holding the syringe in between the thumb and index 
finger until complete resuspension. This action should be repeated, as necessary. If 
appearance is otherwise, the vaccine should not be administered. 
If V114 is provided as a vial: Prior to administration of study vaccine, the unblinded 
pharmacist should use rapid, horizontal hand-shaking for up to 5 seconds while holding the 
vial in between the thumb and index finger to obtain a homogenous white suspension. This 
action should be repeated, as necessary. If appearance is otherwise, the vaccine should not be 
administered. 
The vaccine should not be used if the vaccine cannot be resuspended.
All safety and immunogenicity assessments will be conducted by blinded personnel, and the 
participant or participant’s parent/guardian will be blinded to the study vaccine received by 
the participant. Vaccination information, such as Component Identification Number and time 
of vaccination, must be recorded on the appropriate eCRF as per the Data Entry Guidelines.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
52
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
A 0.5-mL intramuscular dose of study vaccine will be administered to healthy infants at 
approximately 2, 4, 6, and 12 to 15 months of age. Prevnar 13™will be supplied as a pre-
filled syringe.
The vaccines should be administered at a 90° angle in the anterolateral thigh muscle using 
the provided syringes with the following needle length and gauge specifications: 1 inch 
needle, 22 to 25 gauge for infants (2 to 6 months) and 1 to 1¼ inch needle, 22 to 25 gauge for 
toddlers (12 to 15 months). Needles provided in Prevnar 13™ blister packages may also be 
used.
The study vaccines are to be administered at the locations recommended in Table 4. If an 
abnormality (ie, rash) is observed at the site where the previous dose of the study vaccine 
was administered, it is permissible to use the anterolateral muscle of the other limb to 
administer the following dose of the study vaccine.
Unblinded study personnel should follow the preparation and administration instructions for 
Prevnar 13™ as specified in the product label.
8.1.8.1
Timing of Dose Administration
V114 or Prevnar 13™ will be administered as indicated in Section 1.3. Other pediatric 
vaccines will be administered concomitantly on the same day as study vaccine according to 
the recommended schedule (Section 6.5). All participants will be observed for 30 minutes
following each vaccination for any immediate reactions. This observation must be performed 
by blinded site personnel for V114 and Prevnar 13™ (Section 1.3 and Section 6.3.3).
Participants must be afebrile for at least 72 hours prior to vaccination. 
Blood samples must be collected before study vaccination, when applicable.
8.1.9
Electronic Vaccination Report Card
The eVRC was developed to be administered electronically via a hand-held device. This item 
was structured as recommended in the final Food and Drug Administration Patient Reported 
Outcome Guidance [U.S. Food and Drug Administration 2009]. The investigator or delegate 
will train the participant’s legally acceptable representative in the use of the eVRC as 
indicated in Section 1.3.
Body temperatures, injection-site reactions, vaccine-specific complaints, other complaints or 
illnesses, and concomitant medications or non-study vaccinations will be recorded on the 
eVRC as described in Section 1.3 and Section 8.3.3. The investigator or delegate will review 
the data captured on the eVRC with the participant’s legally acceptable representative as 
indicated in Section 1.3.
For the AEs outlined above, the investigator will use the information provided by the 
participant’s legally acceptable representative both on the eVRC, and verbally at the time of 
eVRC review, to apply the appropriate assessment of intensity as described in Appendix 3.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
53
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
8.1.10
Telephone Contact Guide for Day 15 Post Each Dose
Site personnel will contact study participants on Day 15 post each dose to review eVRC data 
with the participant’s legally acceptable representative. The Day 15 Postdose Telephone 
Contact Guide will be provided by the Sponsor. This guide is designed to assist site 
personnel to collect any updates or edits to data previously entered on the eVRC from the 
participant’s legally acceptable representative. Any differences between eVRC data and the 
clinical database must be clearly explained in the participant’s source documentation with an 
indication of where the information was obtained (eg, from the Day 15 Postdose Telephone 
Contact with the participant’s legally acceptable representative).
8.1.11
Telephone Contact Questionnaire
Site personnel will contact study participants approximately 6 months after the last dose of 
study vaccine to collect additional information based on a Telephone Contact Questionnaire 
provided by the Sponsor. Data to be reported from this discussion will include SAEs and/or 
any updates to previously reported safety information.
8.1.12
Discontinuation and Withdrawal
Participants who discontinue study intervention prior to completion of the protocol-specified 
vaccinations should be encouraged to continue to be followed for all remaining study visits.
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the final study visit (Visit 6) should be performed (at the time of withdrawal). 
Any AEs that are present at the time of withdrawal should be followed in accordance with 
the safety requirements outlined in Section 8.4.
8.1.12.1
Withdrawal From Future Biomedical Research
Consent for future biomedical research may be withdrawn by the participant’s legally 
acceptable representative. Consent may be withdrawn by the legally acceptable 
representative at any time by contacting the principal investigator for the main study. If 
medical records for the main study are still available, the investigator will contact the 
Sponsor using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently, the participant's consent for future biomedical research will be withdrawn. A 
letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the 
responsibility of the investigator to inform the participant’s legally acceptable representative
of completion of withdrawal. Any analyses in progress at the time of request for withdrawal 
or already performed prior to the request being received by the Sponsor will continue to be 
used as part of the overall research study data and results. No new analyses would be 
generated after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by regulatory authorities to retain the main study records) 
or the specimens have been completely anonymized, there will no longer be a link between 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
54
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed. 
8.1.13
Participant Blinding/Unblinding
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the drug used by a participant and/or the dosage 
administered, he/she will contact the emergency unblinding call center by telephone and 
make a request for emergency unblinding. As requested by the investigator or medically 
qualified designee, the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Prior to contacting the emergency 
unblinding call center to request unblinding of a participant’s treatment assignment, the 
investigator who is a qualified physician should make reasonable attempts to enter the 
intensity of the AEs observed, the relation to study intervention, the reason thereof, etc., in 
the medical chart. If it is not possible to record this assessment in the chart prior to the 
unblinding, the unblinding should not be delayed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency unblinding has taken place, the principal investigator, site personnel, and 
Sponsor personnel may be unblinded so that the appropriate follow-up medical care can be 
provided to the participant.
Participants whose treatment assignment has been unblinded by the investigator or medically 
qualified designee and/or nonstudy treating physician must be discontinued from study 
intervention, but should continue to be monitored in the study.
Additionally, the investigator or medically qualified designee must go into the IRT system 
and perform the unblind in the IRT system to update drug disposition. In the event that the 
emergency unblinding call center is not available for a given site in this study, the IRT 
system should be used for emergency unblinding in the event that this is required for 
participant safety.
8.1.14
Calibration of Equipment
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
55
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Documentation of equipment calibration must be retained as source documentation at the 
study site.
8.2
Immunogenicity Assessments
Sera from participants will be used to measure (1) vaccine-induced anti-PnPs serotype-
specific IgG for all the 15 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 
and 33F) contained in V114 using the pneumococcal electrochemiluminescence (PnECL)
v2.0 assay, (2) anti-HBsAg concentration using the hepatitis B ECi assay, and (3) anti-
rotavirus IgA using the EIA.
Blood collection, storage and shipment instructions for serum samples will be provided in the 
operations/laboratory manual.
8.2.1
Pneumococcal Electrochemiluminescence (PnECL)
The Sponsor has developed and optimized a multiplex, ECL-based detection method for the 
quantitation of IgG serotype-specific antibodies to the 15 PnPs serotypes contained in V114. 
The PnECL v2.0 assay is based on the Meso-Scale Discovery technology, which employs 
disposable multi-spot microtiter plates. The benefits of the ECL multiplex technology over 
the prior enzyme-linked immunosorbent assay methodology include speed, equivalent or 
better sensitivity, increased dynamic range, the ability to multiplex, and reduction in required 
serum sample and reagent volumes. The measurement of immune responses to the 15 
serotypes included in V114 is performed using an assay format consisting of 2 groups of 7 
and 8 serotypes each. The PnECL v2.0 assay for all 15 serotypes has undergone validation. 
The validation study evaluated various performance parameters of the assay including 
precision, ruggedness, relative accuracy, dilutional linearity, selectivity, and specificity. The 
validation results were evaluated against pre-specified acceptance criteria for each of the 
parameters.
The WHO Expert Committee on Biological Standardization has recommended that in-house 
assays used in immunogenicity studies designed to evaluate protection against IPD be 
bridged to the WHO reference assay in order to maintain the link between immune responses 
to vaccination and the clinical demonstration of protective efficacy against IPD conferred by 
the 7 conjugated polysaccharides in Prevnar™. In 2012 and 2014, the Sponsor formally 
bridged the original PnECL assay to the WHO IgG enzyme-linked immunosorbent assay
(ELISA) in order to determine the PnECL threshold values that correspond to 0.35 µg/mL in 
the WHO ELISA for each of the 7 Prevnar™ serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) 
and for each of the additional 6 serotypes (1, 3, 5, 6A, 7F, and 19A) in Prevnar 13™.
A confirmatory study was performed to formally bridge the optimized PnECL assay (v2.0) to 
the WHO reference ELISA, and to assess the PnECL threshold values that correspond to 
0.35 µg/mL measured using the WHO ELISA for each of the serotypes in V114, including 
the Prevnar 13™ serotypes and serotypes 22F and 33F, which were not previously assessed. 
The bridging of the optimized PnECL to the WHO ELISA is complete, and the data showed 
good concordance between the PnECL and WHO ELISA around the 0.35 μg/mL threshold 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
56
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
value for all 15 serotypes. It is recommended that a single PnECL threshold value of 0.35 
µg/mL be applied to each of the 15 serotypes.
8.2.2
Hepatitis B Enhanced Chemiluminescence (ECi) Assay
The purpose of the hepatitis B ECi assay is to detect total antibody to human plasma-derived 
HBsAg subtypes ad and ay before and after vaccination with HBsAg containing vaccine(s). 
This is the primary assay used to evaluate the serological response to the vaccine(s). The 
assay is a solid phase sandwich enzyme-labeled immunoassay. Results for the assay are 
reported in mIU/mL.
This assay involves the reaction of anti-HBs in a test sample with HBsAg (ad and ay 
subtypes) coated onto the wells. A horseradish peroxidase (HRP)-labeled HBsAg conjugate 
(ad and ay subtypes) then formed a complex with the bound anti-HBs, forming an “antigen 
sandwich”. Unbound materials were removed by washing. A reagent that contained 
luminogenic substrates (a luminol derivative and a peracid salt) and an electron transfer agent 
was added to the wells. The HRP in the bound conjugate catalyzed the oxidation of the 
luminol derivative, producing light. The electron transfer agent increased the level and 
duration of the light produced. The amount of HRP conjugate bound and subsequent light 
produced was indicative of the concentration of anti-HBs present in the sample.
Three internally prepared control serum pools, consisting of a high-positive, low-positive, 
and negative control, were used to monitor the performance of the assay. These pools were 
each prepared from 4 individual human immune sera obtained from an external vendor. 
Additionally, there were anti-HBs positive and negative manufacturer-supplied controls, 
which were prepared from freeze-dried recalcified human plasma. The hepatitis B WHO
International reference standard at 10 mIU/mL was also run as a control in every assay. The 
lower limit of quantification (LLOQ) of the assay is 5 mIU/mL.
8.2.3
Rotavirus Serum IgA Enzyme-Linked Immunosorbent Assay (EIA)
The purpose of the Rotavirus serum IgA EIA is to detect IgA antibody to Rotavirus before 
and after vaccination with rotavirus-containing vaccine. This is one of the primary assays 
used by the Laboratory for Specialized Clinical Studies, Division of Infectious Diseases of 
Cincinnati Children’s Hospital Medical Center to evaluate the serological response to the 
vaccine. This assay is used to detect and quantify anti-rotavirus IgA from serum. Results for 
the assay are reported as units/mL anti-rotavirus IgA.
This assay is run in a standard EIA format. Microtiter plates are coated with a rabbit 
anti-rotavirus IgG antibody. Rotavirus lysate (positive wells) from the WC3 strain of the 
virus and Mock Infected lysate (negative wells) from the MA104 cell line are added to the 
coated microtiter plates. After incubation and washing, standards, controls, and serum 
dilutions are added. The negative wells allow for measurement of rotavirus specific response 
by correcting each sample, control, and standard curve serum optical density (OD) for 
non-specific antibody binding. IgA antibody detection occurs by first adding a biotinylated 
anti-human IgA to the wells, followed by an avidin-biotin-peroxidase complex and substrate. 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
57
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
The quantity of anti-rotavirus IgA is determined by comparison of the delta OD (DOD) from 
sample wells to the standard curve. The DOD is defined as the average of the positive well 
ODs minus the average of the negative well ODs. All serum samples are run in duplicate at 
2 dilutions. A cut-off of ≤1.15 units/mL was derived during the assay validation.
8.3
Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided below. The total amount of blood to be drawn over the course of the study (from 
prestudy to poststudy visits), including approximate blood volumes drawn by visit and by 
sample type per participant, can be found in Section 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1
Physical Examinations
A complete physical examination will be performed at Visit 1. A targeted physical 
examination will be performed at subsequent vaccination visits (Visits 2, 3, and 5). Any 
clinically significant abnormality will be recorded on the appropriate eCRF.
The full and targeted physical examination procedures both include obtaining vital signs 
(heart rate, respiratory rate, and rectal temperature), auscultation of the heart and lung, and 
examination of the abdomen. In addition, a full physical examination will include an 
assessment of the head, eyes, ears, nose and throat (HEENT), skin, lymph nodes, 
neurological system, and musculoskeletal system.
Findings related to the physical examinations should be documented in the participant’s 
chart/source documentation.
8.3.2
Body Temperature Measurement
Pre-vaccination rectal temperatures will be taken by study staff at Visits 1, 2, 3, and 5. 
Participants who have febrile illness (rectal temperature ≥38.1°C [≥100.5°F] or axillary 
temperature ≥37.8°C [≥100.0°F]) occurring at or within 72 hours of Visits 1, 2, 3 and 5 must 
be rescheduled. Rectal is the preferred method of obtaining participant’s temperature. 
Axillary (underarm) is an acceptable method but temperature needs to be confirmed by rectal 
measurement if fever is detected. If an axillary temperature is reported to be ≥37.8°C 
(≥100.0°F), a rectal temperature must be taken. In this case, both axillary and rectal 
temperatures must be recorded on the eVRC. Temperature readings should be taken at 
approximately the same time each day. Use of temporal or tympanic thermometers to collect 
temperature for this study is prohibited.
The participant’s legally acceptable representative will be asked to record a rectal 
temperature reading on the eVRC from Day 1 through Day 7 following each vaccination. 
Temperature measurement must be recorded in the eVRC if fever is suspected during Day 8 
through Day 14.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
58
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
8.3.3
Safety Assessment and Use of the eVRC
All participants will be observed for 30 minutes after each vaccination for any immediate 
reactions. If any immediate AEs are observed during this period, the time at which the event 
occurred within this timeframe, as well as the event itself, any concomitant medications that 
were administered, and resolution of the event, must be recorded on the appropriate eCRF.
Participant’s legally acceptable representative will use the eVRC (Section 8.1.9) to document 
the following information:
•
Rectal temperatures measured Day 1 (day of vaccination) through Day 7 following each 
vaccination; Day 8 through Day 14 following each vaccination if fever is suspected
•
Solicited injection-site AEs (swelling, redness, pain or tenderness, and hard lump) Day 1 
through Day 14 postvaccination
•
Solicited systemic AEs (irritability, drowsiness, appetite lost, and hives or welts) Day 1 
through Day 14 postvaccination
•
Any other unsolicited injection-site or systemic AEs Day 1 through Day 14 
postvaccination
•
The limb that was used for the administration of V114 or Prevnar 13™ (Note: the study 
will report injection-site AEs from V114 or Prevnar 13™ and not from concomitant 
injectable vaccines; the location of V114 or Prevnar 13™ administration can be used by
the participant’s legally acceptable representative to monitor the appropriate limb for 
injection-site AEs related to V114 or Prevnar 13™)
•
Use of any analgesic or antipyretic on the day of vaccination
•
Concomitant medications and non-study vaccinations Day 1 to Day 14 postvaccination
8.3.4
Clinical Laboratory Assessments
There are no laboratory safety evaluations required by the protocol.
8.4
Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by the participant's 
legally acceptable representative).
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
59
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators remain responsible for following up AE, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality.
8.4.1
Time Period and Frequency for Collecting AE, SAE, and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the consent form is signed 
but before allocation/randomization must be reported by the investigator if they cause the 
participant to be excluded from the study, or are the result of a protocol-specified 
intervention, including but not limited to washout or discontinuation of usual therapy, diet, 
placebo treatment, or a procedure.
All AEs, SAEs, and other reportable safety events must be reported by the investigator from 
the day of allocation/randomization to the first vaccination and from the day of each 
vaccination through 14 days postvaccination. SAEs must also be reported throughout the 
duration of the individual’s participation in the study, regardless of whether or not related to 
the Sponsor’s product.
Additionally, any SAE brought to the attention of an investigator at any time outside of the 
time period specified in the previous paragraph also must be reported immediately to the 
Sponsor if the event is either:
1.
A death that occurs prior to the participant completing the study.
OR
2.
An SAE that is considered by an investigator who is a qualified physician to be 
vaccine-related.
Investigators are not obligated to actively seek AE or SAE or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 5.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
60
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Table 5
Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events
Type of Event
Reporting Time 
Period:
Consent to 
Randomization/ 
Allocation
Reporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol-
Specified Follow-
up Period
Reporting Time 
Period:
After the Protocol 
Specified Follow-up 
Period
Timeframe 
to Report 
Event and 
Follow-up 
Information 
to 
SPONSOR
Non-Serious Adverse 
Event (NSAE)
Report if:
- due to protocol-
specified 
intervention
- causes exclusion
- participant is 
receiving placebo 
run-in or other 
run-in treatment
Report all
Not required
Per data entry 
guidelines
Serious Adverse Event 
(SAE)
Report if:
- due to protocol-
specified 
intervention
- causes exclusion
- participant is 
receiving placebo 
run-in or other 
run-in treatment
Report all
Report if:
- drug/vaccine related
- any death until 
participant completion 
of study
(Follow ongoing to 
outcome)
Within 24 
hours of 
learning of 
event
Pregnancy/Lactation 
Exposure
Not applicable since participants are infants.
Event of Clinical 
Interest 
There are no Events of Clinical Interest for this study.
Not 
Applicable
Cancer
Report if:
- due to 
intervention
- causes exclusion
Report all
Not required
Within 5 
calendar days 
of learning of 
event
Overdose
Report if:
- receiving 
placebo run-in or 
other run-in 
medication 
Report all
Not required
Within 5 
calendar days 
of learning of 
event
8.4.2
Method of Detecting AEs, SAEs, and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safety events. Open-ended and nonleading verbal questioning of the participant’s legally 
acceptable representative is the preferred method to inquire about AE occurrence.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
61
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
8.4.3
Follow-up of AE, SAE, and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE, SAE, and other reportable safety events 
including cancer and overdose will be followed until resolution, stabilization, until the event 
is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonserious AEs that occur in 
randomized participants for outcome. Further information on follow-up procedures is given 
in Appendix 3.
8.4.4
Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. All 
AEs will be reported to regulatory authorities, IRB/IECs, and investigators in accordance 
with all applicable global laws and regulations (ie, per ICH Topic E6 (R2) Guidelines for 
Good Clinical Practice [GCP]).
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory requirements and Sponsor policy and 
forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.
8.4.5
Pregnancy and Exposure During Breastfeeding
Information in this section is not applicable since participants are infants.
8.4.6
Disease-related Events and/or Disease-related Outcomes Not Qualifying as 
AEs or SAEs
This is not applicable to this study.
8.4.7
Events of Clinical Interest (ECIs)
There are no events of clinical interest for this study.
8.5
Treatment of Overdose
In this study, an overdose is the administration of more than 1 dose of any individual study 
vaccine in any 24-hour period.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
62
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
No specific information is available on the treatment of overdose.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Sponsor Clinical Director based on the clinical evaluation of the 
participant.
All reports of overdose must be reported by the investigator within 5 calendar days to the 
Sponsor either by electronic media or paper. Electronic reporting procedures can be found in 
the EDC data entry guidelines. Paper reporting procedures can be found in the Investigator 
Trial File Binder (or equivalent).
8.6
Pharmacokinetics
PK parameters will not be evaluated in this study.
8.7
Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.8
Future Biomedical Research Sample Collection
If the participant’s legally acceptable representative signs the future biomedical research 
consent, the following specimens will be obtained as part of future biomedical research:
•
Buccal swab DNA for future research
•
Leftover study serum at the central laboratory stored for future research after aliquoting 
samples for completion of immunogenicity testing
8.9
Planned Genetic Analysis Sample Collection
Planned genetic analysis samples will not be evaluated in this study.
8.10
Biomarkers
Biomarkers are not evaluated in this study.
8.11
Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study.
8.12
Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure-related details are provided 
in Section 8.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
63
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
8.12.1
Screening
Screening procedures will be conducted at Visit 1 as outlined in Section 1.3.
8.12.2
Treatment Period/Vaccination Visits
Requirements during the treatment period are outlined in Section 1.3.
If the participant develops a new clinical condition during the study that makes him/her
ineligible for the study, the investigator should discuss with the Sponsor Clinical Director as 
soon as possible. The decision to continue the participant on study intervention requires the 
mutual agreement of the investigator, the Sponsor, and the participant’s legally acceptable 
representative.
8.12.3
Discontinued Participants Continuing to be Monitored in the Study
A participant may discontinue from study intervention (including receipt of V114, 
Prevnar 13™ and concomitant vaccines provided in the study) but continue to participate in 
protocol-specified, AE-monitoring activities as outlined in Section 1.3, as long as the 
participant’s legally acceptable representative does not withdraw consent. Blood draws for 
immunogenicity testing could occur if agreed to by the participant’s legally acceptable 
representative at the discretion of the investigator.
9
STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study. If, after the 
study has begun, but prior to any unblinding, changes are made to primary and/or secondary 
hypotheses, or the statistical methods related to those hypotheses, then the protocol will be 
amended (consistent with ICH Guideline E-9). Changes to exploratory analyses made after 
the protocol has been finalized, but prior to unblinding, will be documented in a 
supplemental SAP (sSAP) and referenced in the Clinical Study Report (CSR) for the study. 
Post hoc exploratory analyses will be clearly identified in the CSR.
9.1
Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
64
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Study Design Overview
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the 
Interchangeability of V114 and Prevnar 13™ with Respect to Safety, 
Tolerability, and Immunogenicity in Healthy Infants (PNEU-
DIRECTION)
Intervention Assignment
Participants will be randomly assigned in a 1:1:1:1:1 ratio to a complete 
dosing schedule of V114 or Prevnar 13™or one of 3 mixed dosing 
schedules of Prevnar 13™/V114 vaccination groups as specified below:
Group 1: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →Prevnar 13™
Group 2: Prevnar 13™ →Prevnar 13™ →Prevnar 13™ →V114
Group 3: Prevnar 13™ →Prevnar 13™ →V114 →V114
Group 4: Prevnar 13™ →V114 →V114 →V114
Group 5: V114 →V114 →V114 →V114
Analysis Populations
Immunogenicity: Per-Protocol (PP)
Safety: All Participants as Treated (APaT)
Primary Endpoint(s)
Immunogenicity:

Anti-pneumococcal polysaccharide (PnPs) serotype-specific 
Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) 
for the 13 shared serotypes contained in V114 and Prevnar 13™at 
30 days postdose 4 (PD4)
Safety:

Proportion of participants with solicited injection-site AEs (swelling, 
redness/erythema, tenderness/pain, and hard lump/induration) from 
Day 1 through Day 14 following any vaccination with V114 or 
Prevnar 13™

Proportion of participants with solicited systemic AEs (irritability, 
drowsiness/somnolence, appetite lost/decreased appetite, and hives
or welts/urticaria) from Day 1 through Day 14 following any 
vaccination with V114 or Prevnar 13™

Proportion of participants with vaccine-related SAEs from Day 1 
through completion of study participation
Key Secondary Endpoints

Proportion of participants with anti-hepatitis B surface antigen 
(HBsAg) concentration ≥10 mIU/mL at 30 days PD3 of V114 or 
Prevnar 13™

Anti-rotavirus Immunoglobulin A (IgA) Geometric Mean Titer 
(GMT) at 30 days PD3 of V114 or Prevnar 13™

Anti-PnPs serotype-specific IgG GMCs and serotype-specific IgG 
response rates (proportion of participants meeting serotype-specific 
IgG threshold value of ≥0.35 μg/mL) at 30 days following Dose 3 for 
the 15 serotypes contained in V114
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
65
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Statistical Methods for Key 
Immunogenicity Analyses
The primary immunogenicity objective is descriptive without formal 
hypothesis testing. To address the primary immunogenicity objective, the 
serotype-specific IgG GMCs for 13 shared serotypes contained in V114 
and Prevnar 13™ at 30 days PD4 will be compared between groups 
through the estimation of serotype-specific IgG GMC ratios for each of 
the 13 shared serotypes. Estimation of the IgG GMC ratios and 
computation of the corresponding 95% confidence intervals (CIs) will be 
calculated using analysis of covariance (ANCOVA) model with 
vaccination group and stratification factor (hepatitis B vaccination status 
before enrollment = Yes, No) as covariates. The pairwise comparisons
include Group 2 vs Group 1; Group 3 vs Group 1; and Group 4 vs 
Group 1.
To address the secondary objective regarding the non-inferiority 
evaluation of immunogenicity of RECOMBIVAX HB™ when given 
concomitantly with V114 or Prevnar 13™, the proportions of participants 
with anti-HBsAg concentration ≥10 mIU/mL at 30 days PD3 of V114 or 
Prevnar 13™will be compared between groups. The between-treatment 
difference based on the proportions of participants with anti-HBsAg 
concentration ≥10 mIU/mL [V114 (Group 5) minus Prevnar 13™(Group
1 + Group 2)] and its 95% CI will be calculated using stratified Miettinen 
and Nurminen (M&N) method [Miettinen, O. and Nurminen, M. 1985].
To address the secondary objective regarding the non-inferiority 
evaluation of immunogenicity of RotaTeq™ when given concomitantly 
with V114 or Prevnar 13™, the anti-rotavirus IgA GMT at 30 days PD3 
of V114 or Prevnar 13™will be compared between groups through the 
estimation of anti-rotavirus IgA GMT ratios. Estimation of the 
anti-rotavirus IgA GMT ratio [V114 (Group 5)/Prevnar 13™(Group 1 +
Group 2)] and the corresponding 95% CIs will be calculated using
ANCOVA with vaccination group and stratification factor (hepatitis B 
vaccination status before enrollment = Yes, No) as covariates.
Statistical Methods for Key 
Safety Analyses
P-values (Tier 1 endpoints) and 95% CIs (Tier 1 and Tier 2 endpoints) 
will be provided for between-vaccination group differences in the 
percentage of participants with events; these analyses will be performed 
using the M&N method [Miettinen, O. and Nurminen, M. 1985]. The 
pairwise comparisons for Tier 1 and Tier 2 endpoints include Group 2 vs 
Group 1; Group 3 vs Group 1; Group 4 vs Group 1; and Group 5 vs 
Group 1.
Interim Analyses
To support the periodic review of safety and tolerability data across the
V114 Phase 3 pediatric program, an external unblinded statistician will 
provide unblinded interim safety summaries to an independent external 
Data Monitoring Committee (DMC) for their review. There are no plans 
to conduct an interim analysis of unblinded immunogenicity data in this 
study. However, unblinded immunogenicity data will be made available 
to the DMC upon request to enable a benefit-risk assessment.
Multiplicity
No multiplicity adjustment will be made for primary objective as there are no 
formal hypothesis tests associated with primary immunogenicity/safety in 
this study.
No multiplicity adjustments will be made for the two secondary 
objectives/hypotheses for the non-inferiority of V114 and Prevnar 13™ 
when given concomitant use with RECOMBIVAX HB™ and RotaTeq™. 
Both endpoints will be tested individually at the one-sided 0.025 level. 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
66
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Sample Size and Power 
Immunogenicity:
The primary immunogenicity objective for this study is descriptive. The 
study will randomize participants in a 1:1:1:1:1 ratio to the 5 vaccination 
groups. The overall sample size will be approximately 900 with 180 
participants into each of the 5 vaccination groups. There is no hypothesis 
to be evaluated for primary objective. Section 9.9.1 provides information
about the expected variability of the IgG GMC ratios given the sample 
size.
For the hypothesis (H1), the study has ~96% power at a 1-sided 2.5% 
alpha-level to demonstrate that RECOMBIVAX HB™ administered 
concomitantly with V114 is non-inferior to RECOMBIVAX HB™ 
administered concomitantly with Prevnar 13™as measured by the 
proportion of participants with anti-HBsAg concentration ≥10 mIU/mL at 
30 days PD3.
For the hypothesis (H2), the study has ~98% power at a 1-sided 2.5% 
alpha-level to demonstrate that RotaTeq™administered concomitantly 
with V114 is non-inferior to RotaTeq™ administered concomitantly with 
Prevnar 13™as measured by the anti-rotavirus IgA GMT at 30 days 
PD3. Details are provided in Section 9.9.1.
Safety:
Section 9.9.2 provides information about the ability of this study to 
estimate the incidence of AEs within and between the vaccination groups.
9.2
Responsibility for Analyses/In-house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor. This study will be conducted as a double-
blind study under in-house blinding procedures. The official, final database will not be 
unblinded until medical/scientific review has been performed, protocol deviations have been 
identified, and data have been declared final and complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study treatment assignment. Randomization will be implemented in an IRT. Blinding issues 
related to the planned interim analyses are described in Section 9.7.
9.3
Hypotheses/Estimation
Objectives and hypotheses of the study are stated in Section 3.
9.4
Analysis Endpoints
Immunogenicity and safety analysis endpoints that will be evaluated for within- and/or 
between-vaccine differences are listed below.
9.4.1
Immunogenicity Endpoints
A description of immunogenicity assessments is contained in Section 8.2. Immune responses 
will be measured for the 13 shared serotypes contained in V114 and Prevnar 13™ (1, 3, 4, 5, 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
67
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) or all 15 serotypes contained in V114 (1, 3, 4,
5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F).
The primary immunogenicity analysis endpoint includes:
•
Anti-PnPs serotype-specific IgG GMCs for the 13 shared serotypes contained in V114
and Prevnar 13™at 30 days PD4
The secondary immunogenicity analysis endpoints include:
•
Proportion of participants with anti-HBsAg concentration ≥10 mIU/mL at 30 days PD3
of V114 or Prevnar 13™
•
Anti-rotavirus IgA GMT at 30 days PD3 of V114 or Prevnar 13™
•
Anti-PnPs serotype-specific IgG GMCs for the 15 serotypes contained in V114 at 30 
days PD3
•
Anti-PnPs serotype-specific IgG response rates (proportion of participants with IgG 
≥0.35 µg/mL) for the 15 serotypes contained in V114 at 30 days PD3
The exploratory immunogenicity analysis endpoints include:
•
Anti-PnPs serotype-specific IgG GMCs for the 15 serotypes contained in V114 prior to 
Dose 4
•
Anti-HBsAg GMCs at 30 days PD3
9.4.2
Safety Endpoints
A description of safety measures is contained in Sections 8.3 and 8.4. The analysis of safety 
results is described in Section 9.6.2.
Safety and tolerability will be assessed by clinical review of all relevant parameters including 
adverse events and postvaccination temperature measurements following any vaccination 
with V114 or Prevnar 13™.
The safety analysis endpoints include:
•
Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, 
hard lump/induration, and tenderness/pain) from Day 1 through Day 14 following any 
vaccination with V114 or Prevnar 13™
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
68
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
•
Proportion of participants with solicited systemic AEs (irritability, 
drowsiness/somnolence, hives or welts/urticaria, and appetite loss/decreased appetite)
from Day 1 through Day 14 following any vaccination with V114 or Prevnar 13™
•
Proportions of participants with the broad AE categories consisting of any AE, a vaccine-
related AE, an SAE, an AE which is both vaccine-related and serious, and 
discontinuation due to an AE, and the proportion of participants who died
•
Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points Day 1 through Day 7 following any vaccination with 
V114 or Prevnar 13™
9.5
Analysis Populations
9.5.1
Immunogenicity Analysis Populations
The PP population will serve as the primary population for the analysis of immunogenicity 
data in this study. The PP population consists of all randomized participants without 
deviations from the protocol that may substantially affect the results of the immunogenicity 
endpoint(s). Potential deviations that may result in the exclusion of a participant from the PP 
population for all immunogenicity analyses include:

Failure to receive primary infant series vaccination (V114/Prevnar 13™Doses 1, 2, 
and 3) as per randomization schedule

Receipt of prohibited medication or prohibited vaccine prior to study vaccination
Additional potential deviations that may result in the exclusion of a participant from the PP 
population for specific immunogenicity analyses (depending on the timepoint for analysis) 
include:

Failure to receive V114, Prevnar 13™, RECOMBIVAX HB™, or RotaTeq™
according to vaccination schedule required at the timepoint for the analysis

Failure to receive the scheduled doses of V114 or Prevnar 13™(at least 28 days 
between Doses 1 and 2 and between Doses 2 and 3 [for PD3 and pre-dose 4 analysis], 
12 months to 1 day prior to 16 months of age for Dose 4 [for PD4 PP analyses])

Receipt of prohibited medication or prohibited vaccine prior to a blood sample 
collection

Collection of blood sample at the timepoint for the analysis outside of the 
pre-specified window (as described in Section 1.3)
The final determination on protocol deviations, and thereby the composition of the PP 
population, will be made prior to the final unblinding of the database. Participants will be 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
69
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
included in the vaccination group to which they are randomized for the analysis of 
immunogenicity data using the PP population.
A supportive analysis using the Full Analysis Set (FAS) population will also be performed 
for the primary immunogenicity endpoints. The FAS population consists of all randomized 
participants who received all study vaccinations required at the timepoint for the analysis and 
have serology result. Participants will be included in the vaccination group to which they are 
randomized for the analysis of immunogenicity data using the FAS population.
9.5.2
Safety Analysis Populations
Safety analyses will be conducted in the APaT population, which consists of all randomized 
participants who received at least 1 dose of study vaccination. Participants will be included in 
the group corresponding to the study vaccination they actually received for the analysis of 
safety data using the APaT population. This will be the group to which they are randomized 
except for participants who take incorrect study vaccination; such participants will be 
included in the vaccination group corresponding to the study vaccination actually received.
At least 1 temperature measurement obtained subsequent to study intervention is required for 
inclusion in the analysis of temperature.
9.6
Statistical Methods
Statistical testing and inference for immunogenicity and safety analyses are described in
Section 9.6.1 and Section 9.6.2, respectively. Unless otherwise stated, all statistical tests will 
be conducted at the α=0.05 (2-sided) level. Section 9.6.3 describes how demographic and 
baseline characteristics will be summarized.
9.6.1
Statistical Methods for Immunogenicity Analyses
This section describes the statistical methods that address the primary and secondary 
immunogenicity objectives.
Primary Endpoint
The primary endpoint, anti-PnPs serotype-specific IgG GMC for 13 shared serotypes 
contained in V114 and Prevnar 13™at 30 days PD4, is a descriptive endpoint. The primary 
endpoint will be summarized for each vaccination group. The confidence limits for IgG 
GMCs are the exponentiated confidence limits for the mean natural log concentrations, based 
on 1-sample t-distributions. Additionally, the estimation of serotype-specific IgG GMC ratios 
(between-group comparison) for 13 shared serotypes and its 95% CI will be calculated using 
the ANCOVA model utilizing the log-transformed antibody response as the response and 
vaccination group and stratification factor (hepatitis B vaccination status before enrollment =
Yes, No) as covariates. The pairwise comparisons for primary objective include Group 2 vs 
Group 1; Group 3 vs Group 1; and Group 4 vs Group 1. The same approach will be used to 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
70
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
evaluate the secondary endpoint, serotype-specific IgG GMC ratios comparing Group 5 vs 
Group 1.
Secondary Endpoints
Secondary Endpoint #1/Hypothesis (H1)
For the hypothesis (H1), the proportion of participants with anti-HBsAg concentration ≥10 
mIU/mL at 30 days PD3 from participants administered primary infant series dosing 
schedule V114 (Group 5) concomitantly with RECOMBIVAX HB™ will be compared to 
participants administered a complete primary infant series dosing schedule of Prevnar 13™ 
(Group 1 + Group 2) concomitantly with RECOMBIVAX HB™ at 30 days PD3 of V114 or 
Prevnar 13™via the following non-inferiority hypotheses:
H0: p1-p2 ≤-0.10 versus
H1: p1-p2 >-0.10
Where p1 is proportion of participants with anti-HBsAg concentration ≥10 mIU/mL at 30 
days PD3 for Group 5 and p2 is proportion of participants with anti-HBsAg concentration 
≥10 mIU/mL at 30 days PD3 for Group 1 + Group 2.
RECOMBIVAX HB™administered concomitantly with V114 is non-inferior to 
RECOMBIVAX HB™administered concomitantly with Prevnar 13TM if the lower bound of 
the 2-sided 95% CI for the between-treatment difference between Group 5 vs (Group 1 +
Group 2) >-0.10. The proposed 10 percentage point margin is the same as those observed in 
previous Merck vaccine concomitant use studies evaluating similar antigens. The stratified
Miettinen and Nurminen approach will be used for the analysis of this endpoint. The
stratification factor is hepatitis B vaccination status before enrollment (Yes, No) [Miettinen, 
O. and Nurminen, M. 1985].
Secondary Endpoint #2/Hypothesis (H2)
For the secondary hypothesis (H2) , the anti-rotavirus IgA GMTs between participants 
administered a complete primary infant series of V114 (Group 5) concomitantly with 
RotaTeq™ versus participants administered a complete primary infant series dosing schedule
of Prevnar 13™(Group 1 + Group 2) concomitantly with RotaTeq™at 30 days PD3 of 
V114 or Prevnar 13™ will be assessed via the following non-inferiority hypotheses:
H0: GMT1/GMT2 ≤0.50 versus
H1: GMT1/GMT2 >0.50
Where GMT1 is the anti-rotavirus IgA GMT for the V114 (Group 5) and GMT2 is the anti-
rotavirus IgA GMT for the Prevnar 13™(Group 1 + Group 2). A ratio of 0.50 corresponds to 
a 2.0-fold decrease of anti-rotavirus IgA GMT in the V114 as compared with the 
Prevnar 13™. The proposed noninferiority margin of 0.50 for anti-rotavirus responses was 
chosen based on what was observed in a previous Merck concomitant use study for this 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
71
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
endpoint. The anti-rotavirus IgA responses in the V114 group (Group 5) are non-inferior to 
the anti-rotavirus IgA responses in the Prevnar 13™group (Group 1 + Group 2) if the lower 
bound of the 2-sided 95% CI on the GMT ratio (V114/Prevnar 13™) >0.50.
The within-group anti-rotavirus IgA GMT along with 2-sided 95% CIs will be computed. 
Point estimates of anti-rotavirus IgA GMTs are the exponentiated estimates of the mean 
natural log concentrations. The confidence limits for GMTs are the exponentiated confidence 
limits for the mean natural log concentrations, based on 1-sample t-distributions. 
Additionally, anti-rotavirus IgA GMT ratios [V114 (Group 5)/Prevnar 13™(Group 1 +
Group 2)] along with 2-sided 95% CIs will be computed. The 95% CI for the ratio will be 
calculated using the ANCOVA model utilizing the log-transformed antibody titers as the 
response with vaccination group and stratification factor (hepatitis B vaccination status 
before enrollment = Yes, No) as covariates.
For the other secondary endpoints and exploratory continuous descriptive endpoints ;anti-
PnPs serotype-specific IgG GMCs at 30 days PD3 of V114 or Prevnar 13™and prior to
Dose 4 and anti-HBsAg GMCs at 30 days PD3, each vaccination groups will be evaluated
separately. The point estimates will be calculated by exponentiating the estimates of the 
mean of the natural log values and the within-group CIs will be derived by exponentiating 
the CIs of the mean of the natural log values based on the 1-sample t-distribution. For the 
dichotomous endpoints that immune responses meet threshold value as defined in the 
objectives , the within-group CIs will be calculated based on the exact method proposed by 
Clopper and Pearson[Collett, D. 1999].
Reverse Cumulative Distribution Curves for IgG concentrations at 30 days PD3 and 30 days 
PD4 will be graphically displayed by serotype.
A detailed analysis strategy for immunogenicity endpoints is listed in Table 6.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
72
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Table 6
Analysis Strategy for Immunogenicity Variables
Endpoint/Variable
(Description, Time Point)
Primary vs. 
Supportive 
Approach†
Statistical Method‡
Analysis 
Population
Missing 
Data 
Approach
Primary Endpoint
Anti-PnPs IgG GMCs for the 13 shared 
serotypes contained in V114 and 
Prevnar 13™at 30 days PD4
P
ANCOVA§
(estimate, 95% CI)
PP
Missing data 
will not be 
imputed
S
FAS
Secondary Endpoint #1/Hypothesis (H1)
Proportion of participants with anti-
HBsAg concentration ≥10 mIU/mL at 
30 days PD3 of V114 or Prevnar 13™
P
Stratified Miettinen 
and Nurminen¶
(estimate, 95% CI, p-
value)
PP
Missing data 
will not be 
imputed
S
FAS
Secondary Endpoint #2/Hypothesis (H2)
Anti-rotavirus IgA GMT at 30 days 
PD3 of V114 or Prevnar 13™
P
ANCOVA§
(estimate, 95% CI, p-
value)
PP
Missing data 
will not be 
imputed
S
FAS
Other Secondary Endpoints
Anti-PnPs IgG GMCs for the 15 
serotypes contained in V114 at 30 days 
PD3
P
Descriptive Statistics
(estimate, 95% CI)
PP
Missing data 
will not be 
imputed
Proportion of participants with anti-
PnPs IgG ≥0.35 µg/mL for the 15 
serotypes contained in V114 at 30 days 
PD3
P
Descriptive Statistics
(estimate, 95% CIǁ)
PP
Missing data 
will not be 
imputed
†
P = Primary approach; S = Supportive approach.
‡
Statistical models are described in further detail below:
§
ANCOVA model with log-transformed antibody responses as response variable and vaccination group, 
and stratification factor (hepatitis B vaccination status before enrollment = Yes, No) as covariates.
ǁWithin group summaries provided using exact method proposed by Clopper and Pearson.
¶
Stratification factor (hepatitis B vaccination status before enrollment = Yes, No).
CI = confidence interval; FAS = Full Analysis Set; GMC = Geometric Mean Concentration; GMT = Geometric 
Mean Titer; HBsAg = Hepatitis B surface antigen; IgA = Immunoglobulin A; IgG = Immunoglobulin G; PD = 
postdose; PnPs = pneumococcal polysaccharide; PP = Per-Protocol
9.6.2
Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by clinical review of all relevant parameters including 
AEs and postvaccination temperature measurements. The extended safety follow-up period 
will occur 6 months following the last dose of vaccination. Safety and tolerability will be 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
73
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
assessed during the entire study period. Primary safety evaluation will be through 14 days 
post vaccination following any vaccination. Selected safety summaries will be provided for 
the extended safety follow-up period through the end of the study for each vaccine group.
The analysis of safety results following any vaccination will follow a tiered approach (Table
7). The tiers differ with respect to the analyses that will be performed. AEs (specific terms as 
well as system organ class terms) are either pre-specified as “Tier 1” endpoints, or will be 
classified as belonging to "Tier 2" or "Tier 3" based on the number of events observed. The 
pairwise comparisons for Tier 1 and Tier 2 endpoints include Group 2 vs Group 1; Group 3 
vs Group 1; Group 4 vs Group 1; and Group 5 vs Group 1.
Safety analyses will be based on the observed data (ie, with no imputation of missing safety 
data).
Tier 1 Events
Safety parameters or adverse events of special interest that are identified constitute “Tier 1” 
safety endpoints that will be subject to inferential testing for statistical significance with 
p-values and 95% CIs to be provided for between-group differences in the proportion of 
participants with events; these analyses will be performed using the unstratified M&N 
method [Miettinen, O. and Nurminen, M. 1985], an unconditional, asymptotic method. For 
this protocol, solicited injection-site AEs (redness/erythema, swelling, hard lump/induration, 
and tenderness/pain) from Day 1 through Day 14 postvaccination and solicited systemic AEs 
(irritability, drowsiness/somnolence, hives or welts/urticaria, and appetite loss/decreased 
appetite) from Day 1 through Day 14 postvaccination are considered Tier 1 events.
Tier 2 Events
Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences 
in the proportion of participants with events (also via the unstratified M&N method) 
[Miettinen, O. and Nurminen, M. 1985].
Membership in Tier 2 requires that at least 4 participants in any vaccination group exhibit the 
event. The threshold of at least 4 events was chosen because the 95% CI for the between-
group difference in percent incidence will always include zero when vaccination groups of 
equal size each have less than 4 events and thus would add little to the interpretation of 
potentially meaningful differences. Because many 95% CIs for Tier 2 events may be 
provided without adjustment for multiplicity, the CIs should be regarded as a helpful 
descriptive measure to be used in review, not a formal method for assessing the statistical 
significance of the between-group differences in adverse events.
In addition to individual events that occur in 4 or more participants in any vaccination group, 
the broad AE categories consisting of the proportion of participants with any AE, a vaccine-
related AE, an SAE, a vaccine-related SAE, discontinuation due to an AE, and the proportion 
of participants who died will be considered Tier 2 endpoints. The proportion of participants 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
74
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
with maximum temperature measurements meeting the Brighton Collaboration cut points 
will also be considered Tier 2 endpoints.
Tier 3 Events
Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point 
estimates by vaccination group are provided for Tier 3 safety parameters.
Additionally, solicited AEs may be provided following each vaccination by vaccination
group (Groups 1, 2, 3, 4, and 5) in order to better describe the safety of a 4-dose schedule (3 
infant primary series + 1 toddler dose) of PCV when switching from Prevnar 13™ to V114 at 
Doses 2, 3, or 4 during the immunization schedule.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
75
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Table 7
Analysis Strategy for Safety Parameters
Safety 
Tier
Safety Endpoint†
p-Value
95% CI for 
Between-
Group 
Comparison
Descriptive
Statistics
Tier 1
Injection-site redness/erythema (Days 1 to 14)
X
X
X
Injection-site swelling (Days 1 to 14)
X
X
X
Injection-site tenderness/pain (Days 1 to 14)
X
X
X
Injection-site hard lump/induration (Days 1 to 14)
X
X
X
Irritability (Days 1 to 14)
X
X
X
Drowsiness/somnolence (Days 1 to 14)
X
X
X
Hives or welts/urticaria (Days 1 to 14)
X
X
X
Appetite loss/decreased appetite (Days 1 to 14)
X
X
X
Tier 2
Any AE†
X
X
Any Vaccine-Related AE†
X
X
Any SAE†
X
X
Any Vaccine-Related SAE†
X
X
Discontinuation due to AE†
X
X
Death†
X
X
Maximum temperature measurements meeting the 
Brighton Collaboration cut points (Days 1 to 7) 
X
X
Specific AEs by SOC and PT‡ (incidence ≥4 of 
participants in one of the vaccination groups)
X
X
Tier 3
Specific AEs by SOC and PT‡ (incidence <4 of 
participants in all of the vaccination groups)
X
†
These endpoints are broad adverse event categories. For example, descriptive statistics for the safety 
endpoint of “Any AE” will provide the number and percentage of participants with at least one AE.
‡
Includes only those endpoints not pre-specified as Tier 1 or not already pre-specified as Tier 2 endpoints.
AE = adverse event; CI = confidence interval; PT = preferred term; SAE = serious adverse event; 
SOC = system organ class; X = results will be provided
9.6.3
Demographic and Baseline Characteristics
The comparability of the vaccination groups for each relevant demographic and baseline 
characteristic will be assessed by the use of summary tables. No statistical hypothesis tests 
will be performed on these characteristics. The number and percentage of participants 
screened and randomized and the primary reasons for screening failure and discontinuation 
will be displayed. Demographic variables (eg, age, race, and gender, birth weight [kg],
gestational age), baseline characteristics, prior and concomitant vaccinations and therapies 
will be summarized by vaccination group either by descriptive statistics or categorical tables.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
76
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
9.7
Interim Analyses
A periodic review of safety and tolerability data across the V114 Phase 3 pediatric program 
will be conducted by an independent, unblinded, external DMC. A description of the 
structure, function, and guidelines for decision-making by the DMC, along with the timing 
and content of the safety reviews will be outlined in the DMC charter. Information regarding 
the composition of the DMC is provided in Appendix 1. There are no plans to conduct an 
interim analysis of unblinded immunogenicity data in this study. However, unblinded 
immunogenicity data will be made available to the DMC upon request to enable a benefit-
risk assessment.
Study enrollment is likely to be ongoing at the time of any interim analyses. Blinding to 
intervention assignment will be maintained at all investigational sites. The results of interim 
analyses will not be shared with the investigators prior to the completion of the study. 
Participant-level unblinding will be restricted to an external unblinded statistician performing 
the interim analysis.
The DMC will serve as the primary reviewer of the results of the safety interim analyses and 
will make recommendations for discontinuation of the study or protocol modifications to an 
executive committee of the Sponsor (see Appendix 1 for details on the Committees Structure 
for this study). If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study, this Executive Oversight Committee (EOC) of the Sponsor (and 
potentially other limited SPONSOR personnel) may be unblinded to results at the 
intervention level in order to act on these recommendations. The extent to which individuals 
are unblinded with respect to results of interim analyses will be documented by the external 
unblinded statistician. Additional logistical details will be provided in the DMC Charter.
Intervention-level results from the safety interim analysis will be provided by the external 
unblinded statistician to the DMC. Prior to final study unblinding, the external unblinded 
statistician will not be involved in any discussions regarding modifications to the protocol, 
statistical methods, identification of protocol deviations, or data validation efforts after the 
interim analyses.
9.8
Multiplicity
There will be no multiplicity adjustment for the primary immunogenicity objective as there is 
no formal hypothesis testing. No multiplicity adjustments will be made for both secondary 
objectives/hypotheses for the non-inferiority of immunogenicity of V114 and Prevnar 13™ 
when given concomitant use with RECOMBIVAX HB™ and RotaTeq™. Both endpoints 
hypotheses will be tested individually at the one-sided 0.025 level. No multiplicity 
adjustments will be made for the safety comparisons. For assessment of safety endpoints, 
application of a multiplicity adjustment could potentially mask a safety concern. Thus, no 
control of Type I error rate beyond the per-comparison 1-sided α = 0.025 level will be 
applied to the safety analyses, with the realization that spurious statistical significance may 
be observed.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
77
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
9.9
Sample Size and Power Calculations
9.9.1
Sample Size and Power for Immunogenicity Analyses
The primary immunogenicity objective for this study is descriptive. The study will 
randomize participants in a 1:1:1:1:1 ratio to the 5 vaccination groups. The overall sample 
size will be approximately 900 with 180 participants into each of the 5 vaccination groups. It 
is assumed that approximately 135 participants per vaccination group will be evaluable for 
PP immunogenicity analyses at 30 days PD4 (based on a 75% evaluability rate).
For the descriptive primary endpoint IgG GMC, the width of the 95% CIs for the serotype-
specific IgG GMC ratios depend on the sample size, variability of the natural log 
concentrations, and the magnitude of the IgG GMC ratio. The 95% CIs for various 
hypothetical IgG GMC ratios at 30 days PD4 and standard deviation (SD) estimates for the 
natural log titers are displayed in Table 8.
Table 8
95% CIs for Varying Hypothetical IgG GMC Ratios and Varying Standard 
Deviations with 135 Evaluable Participants in Each Vaccination Group
Standard 
Deviation of 
Natural Log 
Titers†
Serotype-specific IgG GMC Ratios†
0.5
0.8
1
1.2
1.5
0.5
(0.44, 0.56)
(0.71, 0.9)  
(0.89, 1.13)
(1.06, 1.35)
(1.33, 1.69)
1
(0.39, 0.64)
(0.63, 1.02)
(0.79, 1.27)
(0.94, 1.52)
(1.18, 1.91)
1.5
(0.35, 0.72)
(0.56, 1.15)
(0.70, 1.43)
(0.84, 1.72)
(1.05, 2.15)
2
(0.31, 0.81)
(0.50, 1.29)
(0.62, 1.61)
(0.74, 1.94)
(0.93, 2.42)
†
The estimates of the standard deviation and IgG GMC ratio are representative of those observed in a 
previous MSD study .
CI = confidence interval; GMC = Geometric Mean Concentration; IgG = Immunoglobulin G
For the secondary endpoints, the power is ~96% and ~98% for each of the 2 non-inferiority
hypotheses when RECOMBIVAX HB™ or RotaTeq™administered concomitantly with 
V114 or Prevnar 13™, respectively.
For the secondary endpoint #1/hypothesis (H1), the study has ~96% power at a 1-sided 
2.5% alpha-level to demonstrate RECOMBIVAX HB™administered concomitantly with 
V114 is non-inferior to RECOMBIVAX HB™ administered concomitantly with 
Prevnar 13™as measured by the proportion of participants with anti-HBsAg concentration 
≥10 mIU/mL 30 days PD3 based on the following assumptions: (1) an approximately 80% 
evaluability rate at PD3 as observed in V114-008 pediatric study; (2) a non-inferiority 
margin of -0.10 for the difference (Group 5 – [Group 1 + Group 2]); and (3) an underlying 
response rate (proportion of participants with anti-HBsAg concentration ≥10 mIU/mL 
30 days PD3 of V114 or Prevnar 13™)of 95% for Prevnar 13™ group as observed in a 
previous MSD study.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
78
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
For the secondary endpoint #2/hypothesis (H2), the study has ~98% power at a 1-sided 
2.5% alpha-level to demonstrate RotaTeq™administered concomitantly with V114 is non-
inferior to RotaTeq™ administered concomitantly with Prevnar 13™as measured by the 
anti-rotavirus IgA GMT at 30 days PD3 based on the following assumptions: (1) an 
approximately 80% evaluability rate at PD3 as observed in V114-008 pediatric study; (2) a 
non-inferiority margin of 2-fold; (3) SD of anti-rotavirus IgA responses in log scale is 1.7 as 
those observed in previous Merck study, and (4) the true GMT ratio (Group 5/[Group 1 +
Group 2]) for anti-rotavirus IgA responses is 1.0.
9.9.2
Sample Size and Power for Safety Analyses
The probability of observing at least 1 SAE in this study depends on the number of 
participants vaccinated and the underlying incidence of participants with an SAE in the study 
population. Calculations below assume that 100% of the randomized participants will be 
evaluable for safety analyses. There is an 80% chance of observing at least one SAE among 
180 participants in each of the complete and mixed dosing regimens of V114 and 
Prevnar 13™if the underlying incidence of an SAE is 0.89% (1 of every 112 participants 
receiving the vaccine). There is a 50% chance of observing at least one SAE among 180
participants in the complete and mixed dosing regimens of V114 and Prevnar 13™group if 
the underlying incidence of an SAE is 0.38% (1 of every 260 participants receiving the 
vaccine). If no SAEs are observed among 180 participants, this study will provide 97.5% 
confidence that the underlying percentage of participants with an SAE is <2.03% (one in 
every 49 participants).
Table 9 summarizes the percentage point differences between the 2 vaccination groups that 
could be detected with 80% probability for a variety of hypothetical underlying incidences of
an adverse event. These calculations assume 180 participants in each group and are based on 
a 2-sided 5% alpha level. The calculations are based on an asymptotic method proposed by 
Farrington and Manning (1990) [Farrington, C. P. 1990]; no multiplicity adjustments were 
made.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
79
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Table 9
Differences in Incidence of Adverse Event Rates between the 2 Vaccination 
Groups That Can be Detected With an ~80% Probability (Assuming 2-sided 5% alpha level 
with 180 Participants in each Group)
Incidence of Adverse Event
Risk Difference
Complete and mixed dosing 
schedules of V114 (%)
N=180
Prevnar 13™ (%)
N=180
Percentage Points
4.5
0.1
4.4
8.6
2
6.6
13.5
5
8.5
20.6
10
10.6
27
15
12
33
20
13
44.2
30
14.2
Incidences presented here are hypothetical and do not represent actual adverse experiences in either group.
Based on an asymptotic method proposed by Farrington and Manning (1990) [Farrington, C. P. 1990]
9.10
Subgroup Analyses
Subgroup analyses (eg, hepatitis B vaccination status before enrollment = (Yes, No), race,
sex (male, female) will be performed for the primary immunogenicity endpoint and selected 
safety endpoints (summary of AEs and summary of solicited AEs). Details of subgroup 
analyses will be provided in the sSAP.
9.11
Compliance (Medication Adherence)
The number and proportion of randomized participants receiving each vaccination will be 
summarized (Section 9.12).
9.12
Extent of Exposure
The extent of exposure will be summarized by the number and proportion of randomized 
participants administered V114 or Prevnar 13™ and the number and proportion of 
randomized participants administered RECOMBIVAX HB™ and RotaTeq™ at each 
vaccination schedule.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
80
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10
SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1
Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design of clinical trials. In all cases, MSD clinical trials will be conducted in compliance 
with local and/or national regulations (eg, International Council for Harmonisation Good Clinical Practice [ICH-
GCP]) and in accordance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, 
efficacy, and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. 
Alternatively, MSD may conduct outcomes research trials, trials to assess or validate various endpoint 
measures, or trials to determine patient preferences, etc.
The design (ie, participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by MSD personnel to assess the ability to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and general principles of 
Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data 
are verified versus source documentation according to standard operating procedures. Per MSD policies and 
procedures, if fraud, scientific/research misconduct, or serious GCP-noncompliance is suspected, the issues 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
81
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
are investigated. When necessary, the clinical site will be closed, the responsible regulatory authorities and 
ethics review committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather 
than hypothesis testing, in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD’s policy on authorship is consistent with the recommendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics Committee [IEC])
All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant 
changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except 
changes required urgently to protect participant safety that may be enacted in anticipation of ethics committee 
approval. For each site, the ethics committee and MSD will approve the participant informed consent form.
B. Safety
The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or representative), ethics committee, and/or regulatory authorities will have 
access to confidential medical records that might identify the participant by name.
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics committee.
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time- and labor-intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
82
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by MSD and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2
Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.3
Data Protection
Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study-related data will be used by the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
83
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.1.3.1
Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC, or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2
Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to 
verify worksheet/CRF report form data. By signing the consent form, the participant agrees 
to this process. If study documents will be photocopied during the process of verifying 
worksheet/CRF information, the participant will be identified by unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
10.1.3.3
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by those agencies.
10.1.4
Committees Structure
10.1.4.1
Scientific Advisory Committee
This study was developed in collaboration with a Scientific Advisory Committee (SAC). The 
SAC is comprised of both Sponsor and non-Sponsor scientific experts who provide input 
with respect to study design, interpretation of study results, and subsequent peer-reviewed 
scientific publications.
10.1.4.2
Executive Oversight Committee
The Executive Oversight Committee (EOC) is comprised  of members of Sponsor Senior 
Management. The EOC will receive and decide upon any recommendations made by the
external DMC regarding the study.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
84
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.1.4.3
External Data Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study. Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants (Section 9.7) and 
recommend to the EOC whether the study should continue in accordance with the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
10.1.5
Publication Policy
The results of this study may be published or presented at scientific meetings. The Sponsor 
will comply with the requirements for publication of study results. In accordance with 
standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement.
If publication activity is not directed by the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary information and to provide comments.  
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements.
10.1.6
Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study is solely responsible for determining whether the study and its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropriate study locations and study site contact information.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
85
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
By signing this protocol, the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this study or its results to those 
registries. 
10.1.7
Compliance with Law, Audit, and Debarment
By signing this protocol, the investigator agrees to conduct the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of GCP
(eg, International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use GCP: Consolidated Guideline and other generally 
accepted standards of good clinical practice); and all applicable federal, state and local laws, 
rules and regulations relating to the conduct of the clinical study. The Code of Conduct, a 
collection of goals and considerations that govern the ethical and scientific conduct of 
clinical investigations sponsored by MSD, is provided in this appendix under the Code of 
Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by the Sponsor.
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by any court or regulatory 
authority will not be allowed to conduct or work on this Sponsor’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.8
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
86
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copying, review, and audit at reasonable times by representatives of the Sponsor or any 
regulatory authorities. The investigator agrees to promptly take any reasonable steps that are 
requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs.
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICF, pertaining to the conduct of this study must 
be retained by the investigator for 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the Sponsor. No records may be 
transferred to another location or party without written notification to the Sponsor.
10.1.9
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available.
10.1.10
Study and Site Closure
The Sponsor or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor will 
promptly notify that study site’s IRB/IEC.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
87
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.2
Appendix 2: Clinical Laboratory Tests
Not applicable
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
88
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.3
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
10.3.1
Definition of AE
AE definition
•
An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•
NOTE: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, device, 
diagnostic agent, or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufactured by, licensed by, 
provided by, or distributed by the Sponsor for human use in this study.
Events meeting the AE definition
•
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, or are considered clinically significant in the 
medical and scientific judgment of the investigator.
•
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.
•
New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
•
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•
For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
•
Any new cancer or progression of existing cancer.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
89
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Events NOT meeting the AE definition
•
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
•
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•
Surgery planned prior to informed consent to treat a pre-existing condition that has not 
worsened.
•
Refer to Section 8.4.7 for protocol-specific exceptions.
10.3.2
Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.
Results in death
b. Is life-threatening
•
The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
•
Hospitalization is defined as an inpatient admission, regardless of length of stay, even if 
the hospitalization is a precautionary measure for continued observation. (Note: 
Hospitalization for an elective procedure to treat a pre-existing condition that has not 
worsened is not an SAE. A pre-existing condition is a clinical condition that is diagnosed 
prior to the use of an MSD product and is documented in the participant’s medical 
history.
d. Results in persistent or significant disability/incapacity
•
The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions.
•
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) that may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect
•
In offspring of participant taking the product regardless of time to diagnosis.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
90
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
f.
Other important medical events
•
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the above definition. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.
10.3.3
Additional Events Reported
Additional events that require reporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•
Is a cancer
•
Is associated with an overdose
10.3.4
Recording AE and SAE
AE and SAE recording
•
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to 
the event.
•
The investigator will record all relevant AE/SAE information on the AE 
CRFs/worksheets at each examination.
•
It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•
There may be instances when copies of medical records for certain cases are requested by 
the Sponsor. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copies of the medical records before submission to the 
Sponsor.
•
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
91
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Assessment of intensity
•
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•
The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safety event) reported during the study and assign it to 1 of the following 
categories:
-
Mild: An event that is easily tolerated by the participant, causing minimal discomfort 
and not interfering with everyday activities (for pediatric studies, awareness of 
symptoms, but easily tolerated).
-
Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies definitely acting like something is wrong).
-
Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category utilized for rating 
the intensity of an event; and both AE and SAE can be assessed as severe (for
pediatric studies, extremely distressed or unable to do usual activities).
•
Injection site redness, swelling, or hard lump from the day of vaccination through Day 14
postvaccination will be evaluated by maximum size.
Assessment of causality
•
Did the Sponsor’s product cause the AE?
•
The determination of the likelihood that the Sponsor’s product caused the AE will be 
provided by an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•
The following components are to be used to assess the relationship between the 
Sponsor’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor’s 
product caused the AE:
-
Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor’s product such as: reliable history, acceptable compliance assessment (diary, 
etc.), seroconversion or identification of vaccine virus in bodily specimen?
-
Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor’s product? Is the time of onset of the AE compatible 
with a vaccine-induced effect?
-
Likely Cause: Is the AE not reasonably explained by another etiology such as 
underlying disease, other drug(s)/vaccine(s), or other host or environmental factors?
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
92
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
-
Rechallenge: Was the participant re-exposed to the Sponsor’s product in the study?
-
If yes, did the AE recur or worsen?
-
If yes, this is a positive rechallenge.
-
If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent 
disability, or (2) the study is a single-dose vaccine study); or (3) Sponsor’s product(s) is/are 
used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR’S PRODUCT, OR IF RE-EXPOSURE 
TO THE SPONSOR’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY THE SPONSOR CLINICAL DIRECTOR, AND IF REQUIRED, THE 
IRB/IEC.
-
Consistency with study intervention profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the Sponsor’s 
product or drug class pharmacology or toxicology?
-
The assessment of relationship will be reported on the CRFs /worksheets by an 
investigator who is a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.
-
Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor’s product relationship).
-
Yes, there is a reasonable possibility of Sponsor’s product relationship:
-
There is evidence of exposure to the Sponsor’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor’s product is reasonable. The 
AE is more likely explained by the Sponsor’s product than by another cause.
-
No, there is not a reasonable possibility of Sponsor’s product relationship:
-
Participant did not receive the Sponsor’s product OR temporal sequence of the AE 
onset relative to administration of the Sponsor’s product is not reasonable OR the AE 
is more likely explained by another cause than the Sponsor’s product. (Also entered 
for a participant with overdose without an associated AE.)
•
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
•
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•
The investigator may change his/her opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality assessment.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
93
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
•
The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow-up of AE and SAE
•
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Sponsor to 
elucidate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•
New or updated information will be recorded in the CRF.
•
The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5
Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool
•
The primary mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
•
Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
•
If the electronic system is unavailable for more than 24 hours, then the site will use the 
paper AE Reporting form.
•
Reference Section 8.4.1  for reporting time requirements.
•
The site will enter the SAE data into the electronic system as soon as it becomes 
available.
•
After the study is completed at a given site, the EDC tool will be taken off-line to prevent 
the entry of new data or changes to existing data.
•
If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off-line, then the site can 
report this information on a paper SAE form or by telephone (see next section).
•
Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
94
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
SAE reporting to the Sponsor via paper CRF
•
If the EDC tool is not operational, facsimile transmission or secure e-mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•
In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable with a copy of the SAE data collection tool sent by overnight 
mail or courier service.
•
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•
Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent).
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
95
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.4
Appendix 4: Medical Device Incidents: Definition and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
Not applicable
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
96
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.5
Appendix 5: Collection and Management of Specimens for Future Biomedical 
Research
1. Definitions

Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body responds to a treatment for a disease or condition. 

Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2

Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2

DNA: Deoxyribonucleic acid.

RNA: Ribonucleic acid.
2. Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8.8 will be 
used in various experiments to understand:
•
The biology of how drugs/vaccines work
•
Biomarkers responsible for how a drug/vaccine enters and is removed by the body
•
Other pathways drugs/vaccines may interact with
•
The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by the Sponsor or those working for or 
with the Sponsor.
3. Summary of Procedures for Future Biomedical Research.

Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in the 
future biomedical research substudy

Informed Consent
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
97
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study visit 
by the investigator or his or her designee. Informed consent for future biomedical 
research should be presented to the participants on the visit designated in the SoA. If 
delayed, present consent at next possible Participant Visit. Consent forms signed by the 
participant will be kept at the clinical study site under secure storage for regulatory 
reasons.
A template of each study site’s approved informed consent will be stored in the Sponsor’s 
clinical document repository.

eCRF Documentation for Future Biomedical Research Specimens
Documentation of participant consent for future biomedical research will be captured in 
the eCRFs. Any specimens for which such an informed consent cannot be verified will be 
destroyed.

Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined in 
the SoA. In general, if additional blood specimens are being collected for future 
biomedical research, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4. Confidential Participant Information for Future Biomedical Research
In order to optimize the research that can be conducted with future biomedical research 
specimens, it is critical to link participant' clinical information with future test results. In 
fact little or no research can be conducted without connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like gender, age, medical history and treatment outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single-coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research 
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
5. Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices. Analyses utilizing the future biomedical research specimens may be performed 
by the Sponsor, or an additional third party (eg, a university investigator) designated by 
the Sponsor. The investigator conducting the analysis will follow the Sponsor’s privacy 
and confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope of analysis outlined in this substudy. Future biomedical research 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
98
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
specimens remaining with the third party after specific analysis is performed will be 
reported to the Sponsor.
6. Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical research and ask that their 
biospecimens not be used for future biomedical research. Participants may withdraw 
consent at any time by contacting the principal investigator for the main study. If medical 
records for the main study are still available, the investigator will contact the Sponsor 
using the designated mailbox (clinical.specimen.management@merck.com). 
Subsequently, the participant's specimens will be flagged in the biorepository and 
restricted to main study use only. If specimens were collected from study participants 
specifically for future biomedical research, these specimens will be removed from the 
biorepository and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsibility of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable. 
Any analyses in progress at the time of request for withdrawal/destruction or already 
performed prior to the request being received by the Sponsor will continue to be used as 
part of the overall research study data and results. No new analyses would be generated 
after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by regulatory authorities to retain the main study 
records) or the specimens have been completely anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7. Retention of Specimens
Future biomedical research specimens will be stored in the biorepository for potential 
analysis for up to 20 years from the end of the main study. Specimens may be stored for 
longer if a regulatory or governmental authority has active questions that are being 
answered. In this special circumstance, specimens will be stored until these questions 
have been adequately addressed.
Specimens from the study site will be shipped to a central laboratory and then shipped to 
the Sponsor-designated biorepository. If a central laboratory is not utilized in a particular 
study, the study site will ship directly to the Sponsor-designated biorepository. The 
specimens will be stored under strict supervision in a limited access facility which 
operates to assure the integrity of the specimens. Specimens will be destroyed according 
to Sponsor policies and procedures, and this destruction will be documented in the 
biorepository database.
8. Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
99
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant or the participant’s legally acceptable representative include: Lack of 
relevance to participant health, limitations of predictive capability, and concerns 
regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapidly report this information to doctors and participants. Participants will not be 
identified by name in any published reports about this study or in any other scientific 
publication or presentation.
10. Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnosed and treated on Sponsor 
clinical studies for future biomedical research.
11. Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the Future Biomedical Research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12. Questions
Any questions related to the future biomedical research should be emailed directly to 
clinical.specimen.management@merck.com.
13. References
1. National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618
2. International Conference on Harmonisation [Internet]: E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy-
single/article/definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-
genomic-data-and-sample-cod.html 
3. Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope 
and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i-pwg.org/ 
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
100
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
4. Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
101
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.6
Appendix 6: Country-specific Requirements
Not applicable
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
102
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
10.7
Appendix 7: Abbreviations
Abbreviation
Expanded Term
ACIP
Advisory Committee on Immunization Practices
Admin
administration
AE
adverse event 
ANCOVA
analysis of covariance
APaT
All Participants as Treated
CI
confidence interval
CONSORT
Consolidated Standards of Reporting Trials
CRF
case report form
CSR
Clinical Study Report
DMC
Data Monitoring Committee
DNA
deoxyribonucleic acid 
ECi
enhanced chemiluminescence
ECL
electrochemiluminescence
eCRF
electronic case report form
EDC
electronic data collection 
EIA or ELISA
enzyme-linked immunosorbent assay
EMA
European Medicines Agency
EOC
Executive Oversight Committee
eVRC
Electronic Vaccination Report Card
FAS
Full Analysis Set
FDAAA
Food and Drug Administration Amendments Act
GCP
Good Clinical Practice 
GMC
Geometric Mean Concentration
GMT
Geometric Mean Titer
HBsAg
hepatitis B surface antigen
HEENT
head, eyes, ears, nose and throat
HIV
human immunodeficiency virus
IB
Investigator’s Brochure 
ICF
Informed Consent Form
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
IgA
Immunoglobulin A
IgG
Immunoglobulin G
IM
intramuscular
IMP
investigational medicinal product
IPD
invasive pneumococcal disease
IRB
Institutional Review Board 
IRT
interactive response technology
M&N
Miettinen and Nurminen
MSD
Merck Sharp & Dohme Corp.
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
103
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
Abbreviation
Expanded Term
NIMP
non-investigational medicinal product
NSAE
non-serious adverse event
PCV
pneumococcal conjugate vaccine
PD
postdose
PnECL
pneumococcal electrochemiluminescence
PnPs
Pneumococcal polysaccharide
PP
Per-Protocol
PT
preferred term
PY
person-years
RNA
ribonucleic acid
SAC
Scientific Advisory Committee
SAE
serious adverse event
SD
Standard deviation
SoA
schedule of activities
SOC
system organ class
SUSAR
suspected unexpected serious adverse reaction
TC
telephone contact
US
United States
WHO
World Health Organization
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
104
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
11
REFERENCES
[Centers for Disease Control 
and Prevention 2008]
Centers for Disease Control and Prevention 
(CDC). Invasive pneumococcal disease in 
children 5 years after conjugate vaccine 
introduction-eight states,1998-2005. MMWR 
Morb Mortal Wkly Rep. 2008 Feb 
15;57(6):144-8.
04KW8S
[Ciapponi, A., et al 2016]
Ciapponi A, Lee A, Bardach A, Glujovsky D, 
Rey-Ares L, Luisa Cafferata M, et al. 
Interchangeability between pneumococcal 
conjugate vaccines: a systematic review and 
meta-analysis. Value Health Reg Issues. 
2016;11C:24-34.
04XCFT
[Collett, D. 1999]
Collett D. Statistical inference for binary data. 
In: Collett D, ed. Modelling Binary Data. 
New York: Chapman & Hall, 1999:17-42.
03NVVC
[Drijkoningen, J. J 2014]
Drijkoningen JJ, Rohde GG. Pneumococcal 
infection in adults: burden of disease. Clin 
Microbiol Infect. 2014 May;20 Suppl 5:45-
51.
04NFHN
[Farrell, D. J, et al 2007]
Farrell DJ, Klugman KP, Pichichero M. 
Increased antimicrobial resistance among 
nonvaccine serotypes of Streptococcus 
pneumoniae in the pediatric population after 
the introduction of 7-valent pneumococcal 
vaccine in the United States. Pediatr Infect 
Dis J. 2007 Feb;26(2):123-8.
04KWD9
[Farrington, C. P. 1990]
Farrington CP, Manning G. Test Statistics 
and Sample Size Formulae for Comparative 
Binomial Trials with Null Hypothesis of Non-
Zero Risk Difference or Non-Unity Relative 
Risk. Stat Med Vol. 9,1447-1454 (1990)
04FS6L
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
105
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
[Guevara, M., et al 2016]
Guevara M, Barricarte A, Torroba L, Herranz 
M, Gil-Setas A, Gil F, et al. Direct, indirect 
and total effects of 13-valent pneumococcal 
conjugate vaccination on invasive 
pneumococcal disease in children in Navarra, 
Spain, 2001 to 2014: cohort and case-control 
study. Euro Surveill. 2016;21(14).
04KSQ3
[Hicks, L. A., et al 2007]
Hicks LA, Harrison LH, Flannery B, Hadler 
JL, Schaffner W, Craig AS, et al. Incidence of 
Pneumococcal Disease Due to Non-
Pneumococcal Conjugate Vaccine (PCV7) 
Serotypes in the United States during the Era 
of Widespread PCV7 Vaccination, 1998-
2004. J Infect Dis 2007;196:1346-54.
03QT0G
[Jokinen, J., et al 2015]
Jokinen J, Rinta-Kokko H, Siira L, Palmu 
AA, Virtanen MJ, Nohynek H, et al. Impact 
of ten-valent pneumococcal conjugate 
vaccination on invasive pneumococcal 
disease in Finnish children a population-
based study. PLoS One. 2015 Mar 
17;10(3):e0120290.
04KW7F
[Lepoutre, A., et al 2015]
Lepoutre A, Varon E, Georges S, Dorleans F, 
Janoir C, Gutmann L, et al. Impact of the 
pneumococcal conjugate vaccines on invasive 
pneumococcal disease in France, 2001-2012. 
Vaccine. 2015 Jan 3;33(2):359-66.
04KW88
[Lexau, C. A., et al 2005]
Lexau CA, Lynfield R, Danila R, Pilishvili T, 
Facklam R, Farley MM, et al. Changing 
epidemiology of invasive pneumococcal 
disease among older adults in the era of 
pediatric pneumococcal conjugate vaccine. 
JAMA 2005;294(16):2043-51.
03RBPW
[Liu, G. F., et al 2017]
Liu GF, Hille D, Kaplan SS, Goveia MG. 
Postdose 3 G1 serum neutralizing antibody as 
correlate of protection for pentavalent 
rotavirus vaccine. Hum Vaccin Immunother. 
2017;13(10):2357-63.
04XNC5
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
106
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
[Martinelli, D., et al 2014]
Martinelli D, Pedalino B, Cappelli MG, 
Caputi G, Sallustio A, Fortunato F, et al 
Towards the 13-valent pneumococcal 
conjugate universal vaccination: effectiveness 
in the transition era between PCV7 and 
PCV13 in Italy, 2010-2013. Hum Vaccin 
Immunother. 2014;10(1):33-9.
04KW8B
[Metlay, J. P., et al 2006]
Metlay JP, Fishman NO, Joffe M, Edelstein 
PH. Impact of pediatric vaccination with 
pneumococcal conjugate vaccine on the risk 
of bacteremic pneumococcal pneumonia in 
adults. Vaccine 2006;24:468-75.
03RC46
[Miettinen, O. and Nurminen, 
M. 1985]
Miettinen O, Nurminen M. Comparative 
Analysis of Two Rates. Stat Med 1985;4:213-
26.
03QCDT
[Moore, M. R., et al 2015]
Moore MR, Link-Gelles R, Schaffner W, 
Lynfield R, Lexau C, Bennett NM, et al. 
Effect of use of 13-valent pneumococcal 
conjugate vaccine in children on invasive 
pneumococcal disease in children and adults 
in the USA: analysis of multisite, population-
based surveillance. Lancet Infect Dis. 2015 
Feb 3. [Epub ahead of print].
043MRP
[Palmu, A. A., et al 2015]
Palmu AA, Kilpi TM, Rinta-Kokko H, 
Nohynek H, Toropainen M, Nuorti JP, et al. 
Pneumococcal conjugate vaccine and 
clinically suspected invasive pneumococcal 
disease. Pediatrics. 2015 Jul;136(1):e22-7.
04KVRL
[Pilishvili, Tamara, et al 2010]
Pilishvili T, Lexau C, Farley MM, Hadler J, 
Harrison LH, Bennett NM, et al. Sustained 
reductions in invasive pneumococcal disease 
in the era of conjugate vaccine. J Infect Dis 
2010;201(1):32-41.
03R5S4
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
107
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
[Ruckinger, S., et al 2009]
Ruckinger S, van der Linden M, Reinert RR, 
von Kries R, Burckhardt F, Siedler A. 
Reduction in the incidence of invasive 
pneumococcal disease after general 
vaccination with 7-valent pneumococcal 
conjugate vaccine in Germany. Vaccine 
2009;27:4136-41.
03QYQQ
[Schillie, S. F. 2013]
Schillie SF, Murphy TV. Seroprotection after 
recombinant hepatitis B vaccination among 
newborn infants: a review. Vaccine. 
2013;31:2506-16.
04XNBY
[Truck, J., et al 2016]
Truck J, Jawad S, Goldblatt D, Roalfe L, 
Snape MD, Voysey M, et al. The antibody 
response following a booster with either a 10-
or 13-valent pneumococcal conjugate vaccine 
in toddlers primed with a 13-valent 
pneumococcal conjugate vaccine in early 
infancy. Pediatr Infect Dis J. 2016 
Jul;35(7):787-93.
04XDBS
[U.S. Food and Drug 
Administration 2009]
U.S. Food and Drug Administration (CDER, 
CBER, CDRH). Guidance for industry 
patient-reported outcome measures: use in 
medical product development to support 
labeling claims [Internet]. Washington: U.S. 
Department of Health and Human Services; 
2009. Available from: 
https://www.fda.gov/downloads/drugs/guidan
ces/ucm193282.pdf
04MG9J
[Van Damme, P. 2016]
Van Damme P. Long-term protection after 
hepatitis B vaccine. J Infect Dis. 2016 Jul 
1;214:1-3.
04X00F
[Velázquez, F. R., et al 2000]
Velázquez FR, Matson DO, Guerrero ML, 
Shults J, Calva JJ, Morrow AL, et al. Serum 
antibody as a marker of protection against 
natural rotavirus infection and disease. J 
Infect Dis 2000;182:1602-9.
03Q3KY
 
 
04ZGY9
 
 
05PZF8

PRODUCT: V114
108
PROTOCOL/AMENDMENT NO.: 027-00
V114-027-00 FINAL  PROTOCOL
25-JUL-2018
[Wagenvoort, G. H., et al 
2016]
Wagenvoort GH, Knol MJ, de Melker HE, 
Vlaminckx BJ, van der Ende A, Rozenbaum  
MH, et al.  Risk and outcomes of invasive 
pneumococcal disease in adults with 
underlying conditions in the post-PCV7 era, 
The Netherlands. Vaccine. 2016 Jan 
12;34(3):334-40.
04KTDB
[Waight, P. A., et al 2015]
Waight PA, Andrews NJ, Ladhani SN, 
Sheppard CL, Slack MP, Miller E. Effect of 
the 13-valent pneumococcal conjugate 
vaccine on invasive pneumococcal disease in 
England and Wales 4 years after its 
introduction: an observational cohort study. 
Lancet Infect Dis. 2015 May;15(5):535-43.
04KTF2
[Weiss, S., et al 2015]
Weiss S, Falkenhorst G, van der Linden M, 
Imohl M, von Kries R. Impact of 10-  and 13-
valent pneumococcal conjugate vaccines on 
incidence of invasive pneumococcal disease 
in children aged under 16 years in Germany, 
2009 to 2012. Euro Surveill. 2015 Mar 
12;20(10):21057.
04KTFC
[Whitney, Cynthia G., et al 
2003]
Whitney CG, Farley MM, Hadler J, Harrison 
LH, Bennett NM, Lynfield R, et al. Decline in 
invasive pneumococcal disease after the 
introduction of protein-polysaccharide 
conjugate vaccine. N Engl J Med 
2003;348(18):1737-46.
03QT0D
 
 
04ZGY9
 
 
05PZF8